ZAMBIA MEDICINES REGULATORY AUTHORITY



Guidelines For In Vitro Diagnostic Medical Device Market Authorisation Table of Contents (IVD MA ToC)

This document has been adapted from the International Medical Device Regulators Forum (IMDRF) document.

Copyright © 2018 by the International Medical Device Regulators Forum.

TABLE OF CONTENTS

PREFACE	;
INTRODUCTION	}
SCOPE	}
PURPOSE	;
CLASSIFICATION MATRICES	;
DEFINITIONS	}
NUMBERING OF HEADINGS	ł
QUALITY MANAGEMENT SYSTEM CHAPTERS (6A & 6B)4	ł
LANGUAGE REQUIREMENTS	ł
PAGINATION	ł
OTHER GENERAL NOTES	ł
ACRONYMS	5
HIERARCHY PRESENTATION	,
CHAPTER 1 – REGIONAL ADMINISTRATIVE	L
CHAPTER 2 – SUBMISSION CONTEXT)
CHAPTER 3 – ANALYTICAL PERFORMANCE AND OTHER EVIDENCE	ł
CHAPTER 4 – CLINICAL EVIDENCE	L
CHAPTER 5 – LABELLING AND PROMOTIONAL MATERIAL	ł
CHAPTER 6A – QUALITY MANAGEMENT SYSTEM PROCEDURES	1
CHAPTER 6B – QUALITY MANAGEMENT SYSTEM DEVICE SPECIFIC INFORMATION	J
DOCUMENT REVISION HISTORY	,

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 2 of 52

PREFACE

The document herein was produced by the International Medical Device Regulators Forum (IMDRF), a voluntary group of global medical device regulators from around the world. The document has been subject to consultation throughout its development.

INTRODUCTION

This document provides an internationally harmonized, modular, format for use when filing medical device submissions to regulatory authorities for market Authorisation. This document is comprehensive in scope in that it defines the location of both common and regional content for all submission types. As a consequence, not all headings are required for all submission types and/or IMDRF jurisdictions.

This ToC document has been developed with consideration of public comments and experience gained from the pilot testing of the draft ToC version.

The ToC documents are intended to work together with a separate document created for each participating jurisdiction – a classification matrix. The classification matrix defines whether for the given submissions type a heading is required, not required, optional, conditionally required, etc. The classification matrices are the published under the authority of participating authorities and are not products of IMDRF, please consult regional regulator websites for further information.

The release of the first version of the final ToC document makes available harmonized formats for use in filing IVD medical device submissions for market authorisation.

SCOPE

This document was developed for in-vitro diagnostics medical device (IVD) market Authorisation submissions. Market authorisation submissions for combination products are out of scope; refer to each specific regulator for guidance regarding combination products. Submissions to request approval to conduct clinical trials are not within the scope of this document.

The document is intended to provide guidance for industry with flexibility to adapt to the variety of products and future products.

PURPOSE

To create a comprehensive submission structure that can be used as a harmonized international electronic submission format while minimizing regional divergences and indicating where regional variation exists. This document is intended to provide guidance regarding the location of submission elements. This document is intended to work together with a separate document created for each participating jurisdiction – a classification matrix.

This document is not intended to introduce any new regulatory requirements; however, by virtue of being more transparent, it may appear to be introducing new requirements.

CLASSIFICATION MATRICES

As this document is comprehensive in nature, not all headings are required for all submission types and/or jurisdictions. This document is intended to work together with a separate document created for each participating jurisdiction – a classification matrix. The classification matrix defines whether for the given submissions type a heading is required, not required, optional, conditionally required, etc. The classification matrices are to be made available on regional regulators websites.

DEFINITIONS

FULL REPORT - Typically includes a complete, detailed description of the objective of the assessment, the methods and procedures, study endpoint(s), pre-defined pass/fail criteria, deviations, results summary, discussion and conclusions, and may include data. Complete, detailed support of method selection, worst case justification, study endpoint selection, and pass/fail criteria should be included.

SUMMARY- Typically includes a brief synopsis of the assessment (1) purpose, (2) methods and (3) results and (4) discussion and conclusions. Outliers and deviations should be reported with the results. The purpose of the assessment and description of methods should address:

- 1. Why the characteristic being evaluated is of interest; and
- 2. why the particular methods are being used to evaluate the characteristic, if applicable including why a regional or harmonized/recognized standard has or has not been complied with.

HEADING CLASS - Headings are classified as either IMDRF; IMDRF, RF; or Regional.

Heading classification is provided in this document to provide an indication of the relevance of any given heading to a particular jurisdiction. The classification matrices provide further requirement classification by jurisdiction and submission type and should be used as the final reference for information of this type.

IMDRF headings are used by most regulators and are therefore considered an IMDRF heading. Content of IMDRF heading contain common elements and may contain regional elements in addition to the common elements.

• Regional Focus (IMDRF, RF) – content needs to be considered with the specific region in mind and will likely need to be adapted for that region (e.g. regional approval numbers or regulatory history, regional variation in approved or requested intended use/indications for use)

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0 Page 3 of 52

• In cases where not all regulators use the heading, the applicable jurisdictions are listed following the heading classification (e.g. IMDRF (USFDA, HC, JP)).


Regional headings are those that contain no common elements. In this case the heading name is consistent amongst IMDRF members, but the content will be specific and different for each region. Headings are also classified as Regional if they are required by only one jurisdiction.


<u>SUBMISSION</u> – A regulatory submission can be any type of information related to a medical device regulatory process. This includes but is not limited to a request for approval/Authorisation to market a device, any communications relating to the original submission, and any request for modification to an existing approval. The submission types that will be accepted in the format described in this document will be dictated by regional policy.

NUMBERING OF HEADINGS

Numbering should remain consistent regardless of whether the heading is required or not. For example, if Heading CH1.02 is not required for the submission type or jurisdiction, but Headings CH1.01 and CH1.03 are, then the numbering would remain CH1.01 followed by CH1.03.

Letters should be added to the numbering of custom headings to indicate the sequence of presentation. For example, under stability of specimens, CH3.5.01.1 is a custom heading; it should be presented as shown below.





QUALITY MANAGEMENT SYSTEM CHAPTERS (6A & 6B)

Chapter 6A & B of the ToC is written in terms of the quality management system language employed in ISO 13485. Chapter 6A is where the company places the standard operating procedures (SOPs) the company utilizes to implement its overall high level quality management system. Chapter 6B is where the company places the documents and records the company utilizes to implement the quality management system SOPs described in Chapter 6A.

LANGUAGE REQUIREMENTS

Each jurisdiction has its own language requirements. Regional guidance should be sought to ensure that content is provided in a language that is acceptable for the jurisdiction to which the submission will be submitted. Any translated material submitted should be verified for accuracy.

PAGINATION

Pages of the submission should be numbered in such a manner that information can be referenced by page number. This may be done either by consecutively numbering the entire submission, or numbering the pages within a section or chapter (e.g., CH2.4.1-1, CH2.4.1-2).

OTHER GENERAL NOTES

This outline of documentation is to support a smooth documentation process. It remains the applicant's responsibility to ensure all regulatory requirements are met, and that clear and transparent evidence of conformity to these requirements are provided.

Regional regulatory guidance will vary between the IMDRF member regulators and can be found in a variety of locations including the individual regulator's laws, directives, regulations, guidance documents, etc. When any requirements are conflicting between this document and regional documents (e.g. the regional laws, directives, regulations, guidance documents), the regional requirement will take precedence.

For the USFDA and ANVISA, regional regulatory guidance include the categories (1) special controls in a device specific regulation, (2) device-specific guidance document, (3) special controls guidance, (4) special controls guideline, <u>and/or</u> (5) statutory or regulatory criteria.

When submitting to the USFDA please refer to the current version of the following MDUFA IV guidance documents to ensure the content for each heading and the overall electronic format of the submission is sufficient to be accepted for review by the USFDA. For example:

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 4 of 52

- 1. Refuse to Accept Policy for 510(k)s: Guidance for Industry and Food and Drug Administration Staff
- 2. Acceptance and Filing Reviews for Premarket Approval Applications (PMAs): Guidance for Industry and Food and Drug Administration Staff
- 3. eCopy Program for Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff

For the EU, the latest EN ISO version and related Annex Z should be taken as reference to verify the correct presumption of conformity with the essential requirement of Medical Devices Directives.

Note: WHO participates as an Official Observer in the IMDRF and its working groups. Recommendations from WHO are based on the experience of WHO Prequalification assessment, taking the needs of Member States without strong regulatory systems into account.

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 5 of 52

ACRONYMS

ANVISA	National Health Surveillance Agency - Brazil
САРА	Corrective Action and Preventive Action
EU	European Union
GMDN	Global Medical Device Nomenclature
HC	Health Canada
IMDRF	International Medical Device Regulators Forum
JP	Japan
MDUFA	Medical Device User Fee Amendments
NB	Notified Body
PMDA	Pharmaceuticals and Medical Devices Agency, Japan
RF	Regional Focus
TGA	Therapeutic Goods Administration - Australia
ТоС	Table of Contents
USFDA	United States Food and Drug Administration
WHO PQ	World Health Organization Prequalification Team – Diagnostics Assessment

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 6 of 52

HIERARCHY PRESENTATION

The following is a hierarchical presentation of the submission structure. More detailed guidance regarding where elements belong is provided following this table.

CILADTED 1					
CHAPTER I - CH1.01	- REGIONAL ADMINISTRATIVE Cover Letter				
	Submission Table of Contents				
CH1.02 CH1.03	List of Terms/Acronyms				
CH1.04	Application Form/Administrative Information				
CH1.04 CH1.05	Listing of Device(s)				
CH1.06	Quality Management System, Full Quality System or other Regulatory Certificates				
CH1.07	Free Sale Certificate/ Certificate of Marketing Authorisation				
CH1.07	User Fees				
CH1.09	Pre-Submission Correspondence and Previous Regulator Interactions				
CH1.10	Acceptance for Review Checklist				
CH1.11	Statements/Certifications/Declarations of Conformity				
CH1.11.1	Performance and Voluntary Standard				
CH1.11.2	Environmental Assessment				
CH1.11.3	Clinical Trial Certifications				
CH1.11.4	Indications for Use Statement with Rx and/or OTC designation Enclosure				
CH1.11.5	Truthful and Accurate Statement				
CH1.11.6	Declaration of Conformity				
CH1.12	Letters of Reference for Master Files				
CH1.13	Letter of Authorisation				
CH1.14	Other Regional Administrative Information				
	- SUBMISSION CONTEXT				
CH2.1	Chapter Table of Contents				
CH2.2	General Summary of Submission				
CH2.3	Summary and Certifications for Premarket Submissions				
CH2.4	Device Description				
CH2.4.1	Comprehensive Device Description and Principle of Operation				
CH2.4.2	Material Specifications				
CH2.4.3	Description of Device Packaging				
CH2.4.4	History of Development				
CH2.4.5	Reference and Comparison to Similar and/or Previous Generations of the Device				
CH2.4.6	Substantial Equivalence Discussion				
CH2.5	Indications for Use and/or Intended Use				
CH2.5.1	Intended Use; Intended Purpose; Intended User; Indications for Use				
CH2.5.2	Intended Environment/Setting for use				
CH2.5.3	Pediatric Use				
CH2.5.4	Contraindications for Use				
CH2.6	ilobal Market History				
CH2.6.1	Global Market History				
CH2.6.2	Global Incident Reports and Recalls				
CH2.6.3	Sales, Incident and Recall Rates				
CH2.6.4	Evaluation/Inspection Reports				
CH2.7	Other Submission Context Information				
CHAPTER 3 -	- NON-CLINICAL EVIDENCE				
CH3.1	Chapter Table of Contents				
СН3.2	Risk Management				
СН3.3	Essential Principles (EP) Checklist				
СН3.4	Standards				
CH3.4.1	List of Standards				
CH3.4.2	Declaration and/or Certification of Conformity				
CH3.5	Analytical Performance				
CH3.5.01	Stability of Sample(s)				
CH3.5.01.1	[Study description, study identifier, date of initiation, date of completion]				
CH3.5.01.1.1	Summary				
CH3.5.01.1.2	Full Report				
CH3.5.01.1.3	Statistical Data				
CH3.5.02	Validation of Specimens				
CH3.5.02.1	[Study description, study identifier, date of initiation, date of completion]				
CH3.5.02.1.1	Summary				
CH3.5.02.1.2	Full Report				
CH3.5.02.1.3	Statistical Data				
CH3.5.03	Metrological traceability of calibrator and control material values				

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 7 of 52

CH3.5.03.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.03.1.1	Summary
СН3.5.03.1.2	Full Report
СН3.5.03.1.3	Statistical Data
CH3.5.04	Accuracy of Measurement
CH3.5.04.1	Trueness
CH3.5.04.1.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.04.1.1.1	Summary
CH3.5.04.1.1.2	Full Report
СН3.5.04.1.1.3	Statistical Data
CH3.5.04.2	Precision (Repeatability and Reproducibility)
CH3.5.04.2.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.04.2.1.1	Summary
СН3.5.04.2.1.2	Full Report
СН3.5.04.2.1.3	Statistical Data
CH3.5.05	Analytical Sensitivity
CH3.5.05.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.05.1.1	Summary
СН3.5.05.1.2	Full Report
СН3.5.05.1.3	Statistical Data
CH3.5.06	Analytic Specificity
CH3.5.06.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.06.1.1	Summary
CH3.5.06.1.2	Full Report
CH3.5.06.1.3	Statistical Data
CH3.5.07	High Dose Hook Effect
СН3.5.07.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.07.1.1	Summary
СН3.5.07.1.2	Full Report
СН3.5.07.1.3	Statistical Data
CH3.5.08	Measuring Range of the Assay
CH3.5.08.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.08.1.1	Summary
CH3.5.08.1.2	Full Report
CH3.5.08.1.3	Statistical Data
CH3.5.09	Validation of Assay Cut-off
CH3.5.09.1	[Study description, study identifier, date of initiation, date of completion]
CH3.5.09.1.1	Summary
CH3.5.09.1.2	Full Report
СН3.5.09.1.3	Statistical Data
CH3.5.10	Validation of the Assay Procedure
СН3.5.10.1	[Study description, study identifier, date of initiation, date of completion]
СН3.5.10.1.1	Summary
СН3.5.10.1.2	Full Report
СН3.5.10.1.3	Statistical Data
СН3.6	Other Studies
СН3.6.1	Electrical Systems: Safety, Mechanical and Environmental Protection, and Electromagnetic Compatibility
CH3.6.1.1	[Study description, study identifier, date of initiation, date of completion]
CH3.6.1.1.1	Summary
CH3.6.1.1.2	Full Report
CH3.6.1.1.3	Statistical Data
CH3.6.2	Software/Firmware
CH3.6.2.01	Software/Firmware Description
CH3.6.2.02 CH3.6.2.03	Hazard Analysis Software Requirement Specification
CH3.6.2.03 CH3.6.2.04	Software Requirement Specification Architecture Design Chart
CH3.6.2.04	Software Design Specification
CH3.6.2.06	Traceability Analysis
CH3.6.2.07	Software Life Cycle Process Description
CH3.6.2.08	Software Verification and Validation
CH3.6.2.08.1	[Study description, study identifier, date of initiation]
CH3.6.2.08.1.1 CH3.6.2.08.1.2	Summary Full Report
CH3.6.2.08.1.2 CH3.6.2.08.1.3	Statistical Data
CH3.6.2.09	Revision Level History
CH3.6.2.10	Unresolved Anomalies (Bugs or Defects)
CH3.6.2.11	Cybersecurity
CH3.6.2.12	Interoperability
0113.0.2.12	Interoportubility

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 8 of 52

	Cleaning and Disinfection Validation					
CH3.6.3 CH3.6.3.1	[Study description, study identifier, date of initiation, date of completion]					
СНЗ.6.3.1.1	Summary					
CH3.6.3.1.2	Full Report					
CH3.6.3.1.2	Statistical Data					
CH3.6.4	Usability/Human Factors					
CH3.6.4.1	[Study description, study identifier, date of initiation, date of completion]					
CH3.6.4.1.1	Summary					
CH3.6.4.1.2	Full Report					
CH3.6.4.1.2 CH3.6.4.1.3	Statistical Data					
CH3.6.5	Statistical Data Statistical Data Statistical Data					
CH3.6.5.1	Claimed Shelf-life					
CH3.6.5.1.1	[Study description, study identifier, date of initiation, date of completion]					
CH3.6.5.1.1.1	Summary					
CH3.6.5.1.1.1	Full Report					
CH3.6.5.1.1.3	Statistical Data					
CH3.6.5.2	In Use Stability					
CH3.6.5.2.1	[Study description, study identifier, date of initiation, date of completion]					
CH3.6.5.2.1.1	Summary					
CH3.6.5.2.1.1 CH3.6.5.2.1.2	Full Report					
CH3.6.5.2.1.2	Statistical Data					
CH3.6.5.3	Shipping Stability					
CH3.6.5.3.1	[Study description, study identifier, date of initiation, date of completion]					
CH3.6.5.3.1.1	Summary					
CH3.6.5.3.1.2	Full Report					
CH3.6.5.3.1.3	Statistical Data					
CH3.7	Analytical Performance and Other Evidence Bibliography					
CH3.8	Other Evidence					
CH3.8.1	[Study description, study identifier, date of initiation, date of completion]					
CH3.8.1.1	Summary					
CH3.8.1.2	Full Report					
CH3.8.1.3	Statistical Data					
CHAPTER 4 -	- CLINICAL EVIDENCE					
CH4.1	Chapter Table of Contents					
CH4.2	Overall Clinical Evidence Summary					
CH4.2.1	Expected Values/Reference Ranges					
CH4.2.2	Clinical Evidence Evaluation Report					
СН4.2.3	Device Specific Clinical Studies					
CH4.2.3.1	[Study description, protocol #, date of initiation, date of completion]					
CH4.2.3.1.1						
	Clinical Study Synopsis					
СН4.2.3.1.2	Clinical Study Report					
CH4.2.3.1.2 CH4.2.2.1.3	Clinical Study Report Clinical Study Data					
CH4.2.2.1.3 CH4.2.4	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information					
CH4.2.2.1.3 CH4.2.4 CH4.3	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion]					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5 CH4.5.1 CH4.5.1.1	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 -	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 - CH5.1	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CHAPTER 5 - CH5.1 CH5.2	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 - CH5.1 CH5.2 CH5.3	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4PTER 5 - CH5.1 CH5.2 CH5.3 CH5.4	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 - CH5.1 CH5.2 CH5.3 CH5.4 CH5.5	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 - CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6 CH5.7	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6 CH5.7 CH5.8	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.2 CH4.5.1.3 CHAPTER 5 - CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6 CH5.6 CH5.7 CH5.8 CHAPTER 6A	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.5 CH5.6 CH5.7 CH5.8 CHAPTER 6A CH6A.1	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES Cover Letter					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6 CH5.6 CH5.7 CH5.8 CH5.8 CH6A.1 CH6A.1 CH6A.2	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES Cover Letter Chapter Table of Contents					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.5 CH5.6 CH5.7 CH5.8 CHAPTER 6A CH6A.1 CH6A.2 CH6A.3	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES Cover Letter Chapter Table of Contents Administrative					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.6 CH5.6 CH5.7 CH5.8 CH5.8 CH6A.1 CH6A.1 CH6A.3 CH6A.3.1	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES Cover Letter Chapter Table of Contents Administrative Product Descriptive Information					
CH4.2.2.1.3 CH4.2.4 CH4.3 CH4.3 CH4.4 CH4.5 CH4.5.1 CH4.5.1.1 CH4.5.1.2 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH4.5.1.3 CH5.1 CH5.2 CH5.3 CH5.4 CH5.5 CH5.5 CH5.6 CH5.7 CH5.8 CHAPTER 6A CH6A.1 CH6A.2 CH6A.3	Clinical Study Report Clinical Study Data Clinical Literature Review and Other Reasonable Known Information IRB Approved Informed Consent Forms Investigators Sites and IRB contact information Other Clinical Evidence [Study description, study identifier, date of initiation, date of completion] Summary Full Report Statistical Data - LABELLING AND PROMOTIONAL MATERIAL Chapter Table of Contents Product/Package Labels Package Insert/Instructions for Use e-labelling Patient Labelling Technical/Operators Manual Product Brochures Other Labelling and Promotional Material - QUALITY MANAGEMENT SYSTEM PROCEDURES Cover Letter Chapter Table of Contents Administrative					

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 9 of 52

СН6А.4	Quality management system procedures			
СН6А.5	Management responsibilities procedures			
СН6А.6	Resource management procedures			
СН6А.7	Product realization procedures			
CH6A.7.1	Design and development procedures			
СН6А.7.2	Purchasing procedures			
СН6А.7.3	Production and service controls procedures			
СН6А.7.4	Control of monitoring and measuring devices procedures			
СН6А.8	QMS measurement, analysis and improvement procedures			
СН6А.9	Other Quality System Procedures Information			
CHAPTER 6B	CHAPTER 6B – QUALITY MANAGEMENT SYSTEM DEVICE SPECIFIC INFORMATION			
CH6B.1	Chapter Table of Contents			
CH6B.2	Quality management system information			
CH6B.3	Management responsibilities information			
CH6B.4	Resource management information			
CH6B.5	Device Specific Quality Plan			
CH6B.6	Product realization information			
CH6B.6.1	Design and development information			
CH6B.6.2	Purchasing information			
CH6B.6.3	Production and service controls information			
CH6B.6.4	Control of monitoring and measuring devices information			
CH6B.7	QMS measurement, analysis and improvement information			
CH6B.8	Other Device Specific Quality Management System Information			

27 March 2018 ZAMRA/MA/GUD/0004 V 1.0

Page 10 of 52

Row ID	Heading Class & Level	S	Heading	Common Content	Regional Content
CH1.01	IMDRF, RF	1	Cover Letter	 a) The cover letter should state applicant or sponsor name and/or their authorized representative/s, the type of submission, the common name of the device (if applicable), device trade name or proprietary name (both of the base device and a new name if one is given to the new version/model of the device) and include the purpose of the application, including any changes being made to existing approvals. b) If applicable and accepted by the regulator, it should include information pertaining to any Master Files referenced by the submission. c) If applicable, acknowledgement that a device sample has been submitted or offered alternatives to allow the regulator to view or access the device (when the regulator requests a sample). d) If the submission is requesting approval of a change that is the result of CAPA due to a recall, this should be stated. e) If the submission is in response to a request for information from the regulator this should be stated and the date of that letter should be included as well as any reference number(s). f) If the submission is unsolicited information (where accepted), this should be stated and any related reference number(s) provided. 	 CFDA Attached documents should be signed or sealed USFDA PMA and 510(k) a) mailing address, b) official correspondent(s), c) phone/fax number(s), d) email address(s e) cover letter shall be signed by applicant and have a place of business in US) – 21 CFR 8 f) Device class and panel or classification reguclassified with rationale for that conclusion TGA The covering letter of application needs to be prained by applicant details of the person authorised to list of the person for the context of the person for the person for the person for the person for the person fo
CH1.02	IMDRF	1	Submission Table of Contents	 a) Includes at least level 1 & 2 headings for the entire submission b) Specifies the page number for each item referred to in the table. NOTE: Refer to the Pagination Section of this document for information about submission pagination. 	
CH1.03	IMDRF	1	List of Terms/Acronyms	Terms or acronyms used in the submission that require definition, should be defined here.	
CH1.04	Regional (ANVISA, CFDA, EU, HC, JP, TGA, USFDA, WHO PQ)	1	Application Form/Administrative Information		ANVISA ANVISA's "Manufacturer or Importer Form" (general information related to the application. CFDA Application form shall be filled out and submitte EU Notified Bodies (NBs) will each have their own including details on the submission type (new, new manufacturer, overview of subcontractors and t certificates in case of Own Brand labelling, gen method where applicable, nature of selected sta directive and classification. Consult relevant NI N.B. Under EU legislation, the Own Brand Lab bears the regulatory responsibility of a manufac- technical documentation (see the EU Guideline

CHAPTER 1 – REGIONAL ADMINISTRATIVE

ed by applicants and/or authorized representatives.

nd an authorized rep (if the applicant does not reside or & 814.20(a) (**PMA Only**) gulation or statement that the device has not been on (**510(k) only**)

prepared on company letterhead and to also include; cally when completing the application form in <u>eBusiness</u> b liaise with TGA during the evaluation process ompany

' (form available at www.anvisa.gov.br), containing .

nitted on line (http://125.35.24.156/)

wn application form and company information form, v, renew, changes), administrative data of the d their QMS certification documentation, underlying CE general information of the product, including sterilisation starting materials (e.g. drugs, animal tissue), applicable NB

abeller is to be considered as the legal manufacturer and facturer including the need to dispose of the entire ne on OBL: http://ec.europa.eu/health/medical-

Row ID	Heading Class & Level		Heading	Common Content	Regional Content
CH1.05	IMDRF, RF (ANVISA, CFDA, EU, TGA, USFDA)	1	Listing of Device(s)	A table listing each variant/model/configuration/component/accessory that is the subject of the submission and the following information for each: a) the identifier (e.g. bar code, catalogue, model or part number, UDI) b) a statement of its name/description (e.g. Trade name, size, intended use) NOTE: i. A model/variant/configuration/component/accessory of a device has common specifications, performance and composition, within limits set by the applicant. ii. Typically each item listed should be available for sale. For example, if everything is sold as part of a kit, then this list would only include the kit. You do not need to list all components that may be sold within a kit/set, unless the component is available for sale independently of the kit. iii. This is classified as RF in recognition that identification numbers may vary from jurisdiction to jurisdiction.	devices/files/guide-stds-directives/interpretativ HC Health Canada's "Application and Fee Form" f sc.gc.ca JP PMDA's "Application form" – from http://ww TGA Application forms to include administrative da applicable conformity assessment procedure ar current certification details, manufacturer detail classification. Refer to www.tga.gov.au for the USFDA PMA and 510(k) CDRH Coversheet Form 3514 WHO PQ WHO PQ applications refer to: http://www.who.int/diagnostics_laboratory/ev. ANVISA The grouping (family and systems) of medical requirements which specify the conditions to ex EU The listing should include the relevant Global I Russia NOTE: Any model/variant/configuration of device(s) 1 Medical Device Nomenclature (GMDN) Code their own GMDN Codes/Terms. TGA For all classes of devices the applicant needs to a) The Global Medical Device Nomenclature b) The classification and the applicable classifi For Class 4 IVDs (other than Class 4 Immunon the following: a) Unique Product Identifiers; and b) any variants (see Regulation 1.6 of the There
CH1.06	Regional (ANVISA, CFDA, EU, HC, TGA,		Quality Management System, Full Quality System or other Regulatory		ANVISA Good Manufacturing Practice Certificate (GMI NOTES:

ive_fiche_obl_en.pdf)

' for the risk class and type of application - from www.hc-

ww.pmda.go.jp/

lata of the applicant, application scope (including and type of application (new, change or recertification)), ails, critical supplier details and device details including ne most up to date information.

evaluations/Application/en/

al devices shall be in compliance with ANVISA's establish family or system of medical devices.

l Medical Device Nomenclature (GMDN) Code and Term

) listed should be limited (covered) by a single Global le and Term. The components within a kit/set can have

to include: e (GMDN) Code and Term sification rule

onohaematology reagents) this table should also identify

nerapeutic Goods (Medical Devices) Regulations

MPC) issued by ANVISA, covering the scope of products.

t to change/include manufacturer of Class III or IV devices y ANVISA. However, submission review may be initiated

Page 12 of 52

Row ID	Heading Class & Level	Heading	Common Content	Regional Content
				 prior to GMP certification. In these cases, t Certification has been submitted to ANVIS name, the address of the site to be certified application to ANVISA. The registration or certificate has been issued. b) Device registration renewal submissions of Certificate issued by ANVISA. The docum from ANVISA will be accepted if the GMF final result of the GMP certification proces canceled. <u>CEPDA</u> a) Domestic applicant shall provide:
				WHO PO ISO 13485 certificates.
CH1.07	Regional 1 (ANVISA, CFDA)	Free Sale Certificate/ Certificate of Marketing Authorisation		ANVISA Provide the document/certificate issued by the marketable, attesting that the device is marketa Alternatively, provide a copy of the Inspection

the document proving that the application for the GMP SA should be presented, identifying the manufacturer d and the identification number of the GMP Cert or amendment will only be approved after the GMP

of Class III or IV devices, also requires a valid GMP ment proving that the GMP Certification was requested IP Certificate has not yet been issued. However, if the ess leads to a refusal, the device registration will be

ization code certificate.

mestic medical devices according to Special Procedure of ive Medical Devices, applicant shall provide a notice of rocedure of approval and evaluation for innovative products are produced by entrusted manufacturers, ed manufacturer and consignment agreement shall be ag license shall cover the category of the submitted

by another Notified Body or registrar. CE full quality DD) covering the scope of products when issued by

y management system certificate certifying that the quality is designed and manufactured satisfies CAN/CSA ISO nt systems - Requirements for regulatory purposes. Health icates that have been issued by special third party auditing ccordance with Section 32.1 of the *Medical Devices*

y authority certification referenced within the submission rence certificates requirements will vary based on the hese requirements.

e Regulatory Authority where the medical device is table, without any restriction at their jurisdiction. on Report issued by ANVISA.

Row ID	Heading Class & Level	Heading	Common Content	Regional Content
				 a) Imported Medical Device applicant shall profine i. Supporting documents of marketing A authority of the country (or region) whe located, and the Authorisation/qualific ii. If the product is not managed as a med the Imported medical device applicant documents, quantification certificate o region) where the registration office or b) Applications for extension renewal and chari. Copies of the original registration certificate of all documents on the change of regiini. For Imported Medical Device, the relet the medical device authority of the couregistration office or manufacturing sitis if the change items need not to be appringion) where the overseas applicant's
CH1.08	Regional (ANVISA, EU, USFDA, WHO PQ)	1 User Fees		ANVISA Receipt of the User Fee payment. Information a http://portal.anvisa.gov.br/taxas1 EU Signed quote and agreement for dossier review USFDA PMA and 510(k) FDA User Fee Form (https://userfees.fda.gov/C WHO PQ Attestation of fee payment.
CH1.09	IMDRF, RF	Pre-Submission Correspondence and Previous Regulator Interactions	 a) During the product lifecycle, pre-submission correspondence, including teleconferences or meetings, may be held between the regulator and the applicant. Further, the specific subject device may have been subject to previous regulatory submissions to the regulator. The contents should be limited to the subject device as similar devices are addressed in other areas of the submission. If applicable, the following elements should be provided: i. List prior submissions or pre-submissions where regulator feedback was provided ii. For previous regulatory submission, include identification of applicable submission reference number. iii. For any pre-submission activities that have not previously been assigned any tracking/reference number, include the information package that is submitted prior to pre-submission meetings, the meeting agenda, any presentation slides, final meeting minutes, responses to any action items arising from the meetings, responses to any action items arising from the meetings, responses to any action in prior submissions (i.e., clinical study applications, withdrawn/deleted/denied marketing submission) for the subject device v. Issues identified and advice provided by the regulator in pre-submission 	 <u>CFDA</u> Provide documents when applicable. For example to the provide documents when applicable. For example and the product to the Notified Body, and has not previously been b) For "borderline products", where applicable documentation on communication with an H to the qualification/classification decision o c) In case of transfer from another Notified Body the associated dossier review reports, the late from the existing certification cycle, will nee new notified body to contact the old notified specific date of transfer of application and C

rovide:

Authorisation or certificate of the product issued by where the applicant's headquarter or manufacturing site is ication documents of the enterprise

edical device by authority of the country (or region) where nt is located, applicant shall provide relevant supporting of manufacturer issued by authority of the country (or or manufacturing site is located(for registration).

ange registration shall include:

rtificate of medical device and its appendices, and copies gistration of medical device in China (for).

levant documents if the new market clearance issued by ountry (or region) where the overseas applicant's site is located is required for change items; or description

broved by the medical device authority of the country (or s registration office or manufacturing site is located.

n about User Fee available at:

ew /audits

/OA_HTML/mdufmaCAcdLogin.jsp?legalsel=2&ref=)

mple, innovative medical device communication record

be reviewed is not under application with another en refused or cancelled by another notified body. ble, any rationale, supportive documentation and key a EU Competent Authority and/or COM services, relating on such product.

Body, that status, including any open Non-conformity, and latest audit report and for QMS transfer all audit reports need to be submitted along with a letter of access from the ied body to confirm any open issue. This will allow a l CE marking.

Row ID	Heading Class & Level	S	Heading	Common Content	Regional Content
				 interactions between the regulator and the applicant/sponsor. vi. Explain how and where the prior advice was addressed within the submission OR a) Affirmatively state there has been no prior submissions and/or pre-submission interactions for the specific device that is the subject of the current submission. NOTE The scope of this section is limited to the particular regulator to which the submission is being submitted (i.e. Health Canada does not need pre-submission information relating to interactions with ANVISA). 	
CH1.10	Regional (TGA, USFDA, WHO PQ)	1	Acceptance for Review Checklist		USFDA PMAComplete the checklist and provide section and check is addressed in the submission. See App <i>Premarket Approval Applications (PMAs): Gu Administration Staff Guidance</i> USFDA 510(k)Complete the checklist by answering the prelin indicating the locations of each item on the cheSee the Acceptance Checklist for Traditional 5 <i>Guidance for Industry and Food and Drug Ad</i> TGAIncludes the Supporting data checklistsWHO PQWHO requests submission of a Product Dossie provides dossier section and pages numbers ind in the submission. Refer http://www.who.int/diagnostics_laboratory/evaa=1NOTE: This provides the reviewer with a quick found throughout the dossier.
CH1.11	Regional (ANVISA, HC, EU, TGA, USFDA)	1	Statements/Certificat ions/Declarations of Conformity	NO CONTENT AT THIS LEVEL	NO CONTENT AT THIS I
CH1.11.1	Regional (USFDA)	2	Performance and Voluntary Standard		USFDA Note to RPS Team: USFDA wants this inform request it in Chapter 3 where standards information
CH1.11.2	Regional (USFDA)	2	Environmental Assessment		USFDA PMA a) If claiming categorical exclusion, informati OR b) Provide the environmental assessment (only concerns
CH1.11.3	Regional	2	Clinical Trial		USFDA PMA and 510(k)

nd pages numbers indicating where every item on the appendix A of the *Acceptance and Filing Reviews for Guidance for Industry and Food and Drug*

iminary questions and providing the pages numbers heck is addressed in the submission

510(k)s in **Refuse to Accept Policy for 510(k)s** : Administration Staff

sier Checklist to be completed by the manufacturer which indicating where every item on the checklist is addressed

valuations/140701_pqdx_049_dossier_checklist_v2.pdf?u

ick guide to where evidence for one requirement may be

LEVEL

rmation displayed here in the admin section but will mation other IMDRF members request (List of Standards)

tion to justify the exclusion

ly required for devices that present new environmental

Page 15 of 52

Row ID	Heading Clas & Level	SS	Heading	Common Content	Regional Content
	(USFDA)		Certifications		a) Certification of Compliance with Requiremb) Financial Certification or Disclosure Statem
CH1.11.4	Regional (USFDA)	2	Indications for Use Statement with Rx and/or OTC designation Enclosure		USFDA 510(k) A suggested format for enclosure can be fou http://www.fda.gov/MedicalDevices/Device 080276.htm
CH1.11.5	Regional (ANVISA, CFDA, HC, TGA, USFDA, WHO PQ)	2	Truthful and Accurate Statement		 ANVISA A declaration (per text below), dated and sig of the company: "We declare that the information provided at th proven by documental evidence. We also declat The device will be marketed observing Legislation; The labelling (e.g. labels, instructions o with the Brazilian regulatory requireme period that it will be available on the Bi The device and accessories that accompatentiating the Essential Requirements of Practices established by ANVISA; All the reasonably foreseeable risks we is acceptable in relation to the benefits. The devices delivered to the market will risks that have not been already address by the manufacturer. The company is aware that if the Brazilian regule sanctions established on federal law (Lei nº 643 technical manager of the company are aware the indicated on art. 273 – Decreto Lei nº 2848/194 Health)." CFDA The self-assurance declaration of the authenticitie is issued by applicants and the ones of imported and agents.) HC Attestation that statements in the application a application and in any attached documentation Canada guidance for specific language. TGA Conformity Assessment - Manufacturee a) A statutory declaration is a written statement declaration is signed in the presence of a wit a statutory declaration is a criminal offence http://www.tga.gov.au/industry/manuf-statu

ements of ClinicalTrials.gov (Form FDA 3674) ement (Form FDA 3454 and Form FDA 3455)

found at

ceRegulationandGuidance/GuidanceDocuments/ucm

signed by the legal representative and technical manager

- this submission are truthful and accurate, and can be clare that:
- ng all requirements established by the Brazilian
- s of use, promotional material) of the device complies ments, and will be maintained up to date during all the Brazilian market;
- mpany the device were designed and are manufactured of Safety and Efficacy and the Good Manufacturing
- were identified and promptly mitigated. The residual risk ts obtained by the use of the devices;
- will be continuously monitored in order to identify new essed, according to the Risk Management Plan established

egulatory requirements were not fulfilled, administrative 5437/1977) shall be applied. The legal representative and that they are answerable to the court by any infraction 940 (Criminal Code – Chapter III: Crime against Public

city of submitted data (the ones of domestic products shall ted products shall be issued respectively by applications

n are true and that the information provided in this ion is accurate and complete. Consult current Health

rer's statutory declaration

ent allowing a person to declare something to be true. The witness. Giving false or misleading information as part of ce under the Criminal Code.

tutory-declarations.htm#forms

Row ID	Heading Class & Level	s	Heading	Common Content	Regional Content
CH1.11.6	IMDRF (CFDA, EU, JP, TGA)	2	Declaration of Conformity	As part of the conformity assessment procedures, the manufacturer of a medical device is required to make a Declaration of Conformity that declares that the device complies with: a) the applicable provisions of the Essential Principles/Requirements b) the classification rules c) an appropriate conformity assessment procedure	Statements of undertaking by the manufacturer the Therapeutic Goods (Medical Devices) Reg USFDA 510(k) a) Truthful and Accurate statement per 21 CFR <i>I certify that, in my capacity as (the positio</i> <i>best of my knowledge, that all data and info</i> <i>truthful and accurate and that no material</i> NOTE: Signed by a responsible person of t WHO PQ a) A signed Manufacturer Declaration WHO D attesting that all the information provided in thi b) A letter attesting that the content of the elect CFDA A declaration that : a) The products conforms to the requirem IVD Reagents and relevant laws and re b) the product classification conforms to t Registration of IVD Reagents and Cate JP Declaration and/or certificate that the relevant p principles and/or the quality management syste NOTE: The applicant is advised to prepare the "Conformity Assessment - Supplier's Declaration TGA The wording of the Declaration of Conformity chosen by the manufacturer. Templates for eacl Conformity under Schedule 3 of the Therapeuti available at <http: www.tga.gov.au="">.</http:>
CH1.12	IMDRF	1	Letters of Reference for Master Files	Letter from any Master File owner granting access to the information in the master file. The letter should specify the scope of access granted.	
CH1.13	Regional (ANVISA, CFDA)	1	Letter of Authorisation		ANVISA Letter issued by the manufacturer allowing the behalf, and to market his product on the Brazilia <u>CFDA</u> a) Evidence of power of attorney of the foreign b) Copies of the letter of commitment and busin

rer as required by conformity assessment procedures set in egulations 2002

FR 807.97(k). Text:

tion held in company) of (company name), I believe to the information submitted in the premarket notification are al fact has been omitted.

f the firm (not a consultant)

Document PQDx_049 "Product Dossier Checklist" this product dossier is current and correct. ectronic version is an exact duplicate of the printed copy.

ments of Administrative Measures on the Registration of regulations;

the requirements of Administrative Measures on the stegorized Subdirectories of IVD Reagents;

t product is manufactured to conform to the essential tem.

ne declaration of conformity according to ISO 17050-1 ation of Conformity - Part 1: General Requirement."

y will depend on the conformity assessment procedure ach of the four possible types of Declarations of utic Goods (Medical Devices) Regulations 2002 are

the importer to submit the application to ANVISA on his ilian market.

gn applicant for designating agent in China. siness license or copy of organization registration

Page 17 of 52

D ID	Heading Class & Level		8			
Row ID			Heading	Common Content	Regional Content	
					certificate of agent.	
CH1.14	IMDRF	1	Other Regional	Heading for other information that may be important to the submission but that does not fit		
			Administrative	in any of the other headings of this chapter.		
			Information			

Row ID	Heading Clas & Level	S	Heading	Common Content	Regional Content
CH2.1	IMDRF	1	Chapter Table of Contents	a) Includes all headings and sub-headings for the chapter.b) Specifies the page number for each item referred to in the table.	
CH2.2	IMDRF, RF	1	General Summary of Submission	 a) Statement of the device type (e.g. Tacrolimus test system, blood specimen collection device, calibrator) and name (e.g. trade name, proprietary name), its general purpose, and a high-level summary of key supporting evidence (i.e. studies that are unique to the risks of this device type). b) Summary of submission, including The type of submission (e.g. new, amendment, change of existing application, renewal); if amendment/supplement, the reason of the amendment/supplement; if a change to existing approval, description of the change requested (e.g., changes in design, performance, indications, changes to manufacturing processes, manufacturing facilities, suppliers); iv. any high-level background information or unusual details that the manufacturer wishes to highlight in relation to the device, its history or relation to other approved devices or previous submissions (provides context to submission). 	 <u>ANVISA:</u> If renewal, amendment or change, identification ANVISA for the device, family, system or set must be informed. <u>CFDA</u> a) If product registration, the applicant shall det the classification code b) If registration extension, the applicant shall product. <u>EU</u> If renewal, amendment or change, identification and related certificate of IVDD annex. <u>HC</u> If <u>amendment</u> or new submission based on cur Licence Number(s) should be provided along we certificate numbers must be detailed. <u>USFDA 510(k)</u> Executive Summary
CH2.3	Regional (USFDA)	1	Summary and Certifications for Premarket Submissions		USFDA PMA a) Summary of the Content of the Whole PMA <u>USFDA 510(k)</u> a) 510(k) Summary contains all elements per OR b) 510(k) Statement contains all elements per
CH2.4	IMDRF	1	Device Description	NO CONTENT AT THIS LEVEL	
CH2.4.1	IMDRF, RF	2	Comprehensive Device Description and Principle of Operation	 a) A general description of the device, including: A statement of the device name. What does it detect? Who uses it and for what? (high level statement) Where to use it? (places/environment where the device is intended to be used) General description of the principle of the assay method or instrument principles of operation. Vi. Description of the components (e.g. reagents, assay controls and calibrators) and where appropriate, a description of the reactive ingredients of relevant components (such as antibodies, antigens, nucleic acid primers). 	 <u>ANVISA:</u> a) Some accessories may request independent considered a medical device by itself and is combination. For this accessories shall be in ANVISA provided. <u>CFDA</u> Describe the preparation methods of quality considered and a second second

CHAPTER 2 – SUBMISSION CONTEXT

ion of the registration/notification number issued by et of devices and the number of the original application

describe the management category, criteria for determining

Ill provide the statement that no changes are made to the

ion of product (family) currently Marketed under CE mark

urrently licenced device(s), the Canadian Medical Device g with the description of the change requested.

ssessment certificate, identification of the affected TGA

MA per 21 CFR 814.20(b)(3)

r 21 CFR 807.92

er 21 CFR 807.93

nt submission at ANVISA. Especially when it is is not of exclusive use of the medical device to be used in e identified and heir registration/notification number in

control products and calibrators.

eparately should be identified.

tions are necessary and sufficient to ensure the efficacy,

in Appendix A of the Acceptance and Filing Reviews for Guidance for Industry and Food and Drug 20(f)

ires a photographs of all kit components (packaged and

, WHO PQ requires the following additional information: omponent in the product

eduction of transmission or infection risk

of transmission or infection to the user of the device from action methods have been applied. If there are no such ate that this is the case.

ce are informed of any residual risk

Row ID	Heading Class & Level	s	Heading	Common Content	Regional Content
CH2.4.3	IMDRF	2	-	NOTE: If applicable, chemicals should be identified using either the IUPAC (International Union of Pure and Applied Chemistry) or the CAS (Chemical Abstract Service) Registry number. Reference to applicable material standards may also be useful in this description.a) A brief description of the packaging of the devices, including the packaging	
	(ANVISA, EU, HC, TGA, USFDA) WHO PQ		Device Packaging	configuration and materials involved. This is not intended to include shipping/transport packaging.b) Specific packaging of accessories marketed together with the IVD medical devices shall also be described.	
CH2.4.4	IMDRF (ANVISA, EU, HC, TGA, USFDA, WHO PQ)	2	History of Development	For any device versions/prototypes referenced in the evidence presented in the submission, a table describing the version/name, with 4 columns (Device Name and/or Version; Description of changes from previous row; motivation for the change; list of verification/validation activities, including clinical studies, conducted using this version). For any design verification or validation activities presented in this submission (including clinical studies) performed on any earlier versions of the subject device, include a justification for why the changes do not impact the validity of the data collected under those activities in supporting the safety and performance of the final IVD medical device design.	USFDA 510(k) It is highly recommended that the following be clearance: either a description of all changes ma WHO PQ Provision of the date of design lock down. This signed off, including quality control and quality IFU.
CH2.4.5	IMDRF, RF	2	Reference and Comparison to Similar and/or Previous Generations of the Device	 a) A list of the similar devices (available on local and international market) and/or previous generation of the devices (if existent) relevant to the submission. This should include any similar/previous generation devices that were previously reviewed and refused by the subject regulator. b) Description of why they were selected. c) A key specification comparison, preferably in a table, between the references (similar and/or previous generation) considered and the device. 	 HC a) If the application is an amendment to a licer device, a description of the modifications is indications). b) Comparisons can be used to support the safe currently licensed device in Canada. If this is Licence Number of the comparator is stated manufactured by the same manufacturer.
CH2.4.6	Regional (USFDA)	2	Substantial Equivalence Discussion		 USFDA 510(k) a) Identify the predicate device(s) 510(k) number, trade name and model Ensure the identified predicate device(s) Substantial Equivalence discussion are as those used in comparative performants b) Include a comparison of indications for use principles of operation) between the predicate device do not render the subject device(s) Not Substantial equivalence of safety and effect
CH2.5	IMDRF	1	Indications for Use and/or Intended Use	NO CONTENT AT THIS LEVEL	
CH2.5.1	IMDRF, RF	2	Intended Use; Intended Purpose; Intended User; Indications for Use	 This section should include, <u>as appropriate:</u> a) Intended Use: The statement of intended use should specify what is detected and the function provided by the device (e.g. screening, monitoring, diagnosis or aid to diagnosis). It should identify Instruments on which the device can be used, if the assay is automated or not, is the IVD medical device qualitative or quantitative, and the specimen types (e.g. serum, plasma, urine, cerebrospinal fluid), including 	 <u>USFDA</u> a) For Intended Use/Indication for Use see 21 <u>HC NOTE</u> The content of this section should be contained

be provided for a device that has received prior 510(k) made to the device since the last 510(k) clearance.

his is considered to the date that final documentation is ity assurance specifications, and finalized method in the

cenced device or is based on a modification of a licensed is required (e.g., changes in design, performance, and

afety and effectiveness of the device if they are made to a s method is used, ensure the Canadian Medical Device ed. The comparison device does not need to be

el number

e(s) is consistent throughout the submission (i.e.,

The same as listed in the 510(k) summary and the same nance testing).

se and the technology (including features materials and icate device(s) and subject device(s).

es between the subject device(s) and the predicate device(s) abstantially Equivalent, affect safety or effectiveness or ectiveness.

21 CFR 809.10

ed in a single body of text.

Page 21 of 52

Row ID	Heading Clas & Level	S	Heading	Common Content	Regional Content
Row ID				 any additives that are required (e.g. anticoagulant) b) Intended Purpose: What is the specific disorder, condition or risk factor of interest that it is intended to detect, define or differentiate? c) Intended user: Lay person or professional? d) Identify if the device is intended for single or multiple use e) Indications for Use: i. Disease or medical condition that the device will diagnose, treat, prevent, mitigate, or cure, parameters to be monitored and other considerations related to indication for use. ii. If applicable, information about patient selection criteria. iii. If applicable, information about intended patient population (e.g. adults, pediatrics or newborn) or a statement that no subpopulations exist for the disease or condition for which the device is intended. NOTES: i. The statements of intended use and indications for use must be as presented in the labelling. ii. If more than one device is included, the information should be provided for each device 	
CH2.5.2	IMDRF, RF (ANVISA, EU, HC, TGA, USFDA)	2	Intended Environment/Setting for use	 a) The setting where the device is intended to be used (e.g. domestic use, self-testing, near-patient/point of care). Multiple options can be indicated. b) If applicable, environmental conditions that can affect the device's safety and/or performance (e.g. temperature, humidity, power, pressure, movement). 	USFDA PMA and 510(k) FDA includes this information in the indication
CH2.5.3	Regional (USFDA)	2	Pediatric Use		 <u>USFDA PMA</u> a) Description of any pediatric subpopulation is intended to treat, diagnose or cure, b) The number of affected pediatric patients, OR c) Statement that no pediatric subpopulation intended.
CH2.5.4	Regional (USFDA)	2	Contraindications for Use	If applicable, specify the disease or medical conditions that would make use of the device inadvisable due to unfavorable risk/benefit profile. NOTE: The statement if contraindications for the device must be as presented in the labelling.	USFDA PMA and 510(k) FDA includes this information in the indicatio
CH2.6	IMDRF	1	Global Market History	NO CONTENT AT THIS LEVEL	
CH2.6.1	IMDRF	2	Global Market History	 a) Up to date indication of the markets (all countries or jurisdictions) where the device is already marketed, including any marketing under compassionate use regulations. b) Should include history of the marketing of the device by any other entity in as much detail as possible, acknowledging that detailed information may not be available in all cases. c) If the subject device is different in any way (e.g. design, labelling, specifications) from those approved or marketed in other jurisdiction, the differences should be described. d) The month and year of market introduction in each country or jurisdiction where the device is marketed. If the device has been marketed for greater than 10 years, a statement of greater than 10 years can be made. 	 <u>ANVISA and HC:</u> If there is any approval number, given to the d or jurisdictions) where the device is already m <u>EU</u> The commercial names used by the Original E should be identified. <u>HC</u> a) If applicable, market history should ince

tions for use and product labelling

ons that suffer from the disease or condition that the device

s, as a whole and within each pediatric subpopulation.

on exists for the disease or condition for which the device is

tions for use and product labelling

e device by the regulator authority of the markets (country marketed, this identification must be informed.

Equipment Manufacturer in case of Own Brand Labelling

nclude data for previous generations of the device.

Page 22 of 52

Row ID	Heading Class & Level			Common Content	Regional Content	
				 e) For each of the markets listed in (a) above, and statement of the commercial names used in those markets OR a clear statement that the commercial names are the same in all jurisdictions. f) State the date of data capture for the market history data g) If the subject device has been the subject of any previous compassionate use and/or clinical studies this should be identified and, if applicable, relevant reference numbers provided. 	 b) Information regarding any Canadian Invincluded. HC NOTE: In this context, compassionate <u>TGA</u> Any notifications to foreign regulators of subst 	
CH2.6.2	IMDRF, RF	2	Global Incident Reports and Recalls	 a) List adverse events/incidents associated with the device and a statement of the period associated with this data. b) If the number of events is voluminous, provide a summary by event type that state the number of reported events for each event type. c) List of the IVD medical device recalls and/or advisory notice, and a discussion of the handling and solution given by the manufacturer in each case. d) A description of any analysis and/or corrective actions undertaken in response to items listed above. NOTES It is acknowledged that the definition of recall may vary from one jurisdiction to another; hence this heading is labelled as regionally focused (RF). 	USFDA 510(k) NOTE Include when submitting a 510(k) to implemen US	
CH2.6.3	IMDRF, RF (HC, EU, JP, TGA)	2	Sales, Incident and Recall Rates	 a) A summary of the number of units sold in each country/region and a statement of the period associated with this data. b) Provide the rates calculated as follows for each country/region: Incident rate = # adverse events/incidents divided by # units sold x 100 Recall rate = # recalls divided by # units sold x 100 Rates may be presented in other appropriate units such as per patient year of use or per use. In this case, methods for determining these rates should be presented and any assumptions supported. c) Critical analyses of the rates calculated (e.g. Why are they acceptable? How do they break down in terms of incidents? Is there some outlier data that has driven the rates up? Are there any trends associated with any sub-groups of the devices that are subject of the submission (e.g. size, version)?). NOTES I. It is acknowledged that the definition of recall may vary from one jurisdiction to another; hence this heading is labelled as regionally focused (RF). Sales in this context should be reported as the number of units sold. 		
CH2.6.4	Regional (TGA, WHO PQ)	2	Evaluation/Inspectio n Reports		TGA Copies of Evaluation/Inspection Reports fromWHO PQ Copies of the last 2 Evaluation/Inspection Reports, MDSAP).	
CH2.7	IMDRF	1	Other Submission Context Information	To inform special/additional data that do not fit on previous headings. NOTE: To ensure all elements of your submission are adequately reviewed, please be sure that any content placed here does not belong under any heading described above.		

nvestigational Testing Authorisations should be

ate use includes any Special Access Authorisations.

ostantial change to the device

nent a design change to address a recall of a device in the

m other parties (e.g. Notified Body inspection reports).

eports from other parties (e.g. Notified Body inspection

Row ID	Heading Class & Level	S	Heading	Common Content	Regional Content
СН3.1	IMDRF	1	Chapter Table of Contents	a) Includes major headings for the chapter, to the level of the custom headings.b) Specifies the page number for each item referred to in the table.	
СН3.2	IMDRF	1	Risk Management	 a) A summary of the risks identified during the risk analysis process and how these risks have been controlled to an <u>acceptable</u> level. The summary should address Possible hazards for the IVD medical device for example, the risk from false positive or false negative results and the risk of delays in availability of results Indirect risks which may result from IVD medical device-associated hazards, for example, risk associated with instability, which could lead to erroneous results or user-related hazards, such as reagents containing infectious agents. b) The results of the risk analysis should provide a conclusion with evidence that remaining risks are acceptable when compared to the benefits. c) Where a standard is followed, identify the standard. 	 <u>EU</u> A formal signed statement accepting the rest placing product on the EU market. <u>WHO PO</u> In addition, WHO PQ requires evidence that management plan.
СН3.3	IMDRF (ANVISA, CFDA, EU, JP, TGA, WHO PQ)	1	Essential Principles (EP) Checklist	 a) An EP checklist established for the IVD medical devices, information about method(s) used to demonstrate conformity with each EP that applies, references for the method adopted and identification of the controlled document with evidence of conformity with each method used. b) For the controlled documents indicated which are required for inclusion in the submission: a cross-reference of the location of such evidence within the submission. c) If any EP indicated in the checklist does not apply to the device: a documented rationale of the non-application of each EP that does not apply. NOTE: Methods used to demonstrate conformity may include one or more of the following: a) conformity with recognised or other standards; b) conformity with a nin-house test method(s); c) conformity with an in-house test method(s); d) the evaluation of pre-clinical and clinical evidence; e) comparison to a similar device already available on the market. 	
СН3.4	IMDRF (ANVISA, EU, HC, TGA, USFDA)	1	Standards	NO CONTENT AT THIS LEVEL	
CH3.4.1	IMDRF, RF (ANVISA, CFDA, EU, HC, TGA, USFDA)	2	List of Standards	 a) List the standards that have been complied with in full or in part in the design and manufacture of the device. b) At a minimum should include the standard organization, standard number, standard title, year/version, and if full or partial compliance. c) If partial compliance, a list the sections of standard that i. Are not applicable to the device, and/or ii. have been adapted, and/or iii. were deviated from for other reasons – discussion to accompany 	EU NOTE An overview of used standards typically is a rationales for using standards that are non-ha needs only to be presented once in the applic TGA This list should include any medical device s applied to the device; and, if no medical device only of such a standard, has been applied to device complies with the applicable provision section may be presented in the Essential Pri- once in the application. USFDA PMA and 510(k)

CHAPTER 3 – ANALYTICAL PERFORMANCE AND OTHER EVIDENCE

esidual risk upon completing the risk-benefit analysis before

nat the risk analysis is part of the manufacturer's risk

s added in the essential requirements checklist, including -harmonised or complied with only in part. This information blication.

e standard or conformity assessment standard that has been evice standard or conformity assessment standard, or part to the device — the solutions adopted to ensure that each sions of the essential principles. The information in this Principle Checklist and, if so, needs only to be presented

					If submission references use of a national or substantial equivalence, submission contain
CH3.4.2	Regional (ANVISA, CFDA,HC, USFDA)	2	Declaration and/or Certification of Conformity		CFDA A declaration that the product complies with ANVISA IVDs for blood bank screening requires pre- (INCQS/FioCruz – Instituto Nacional de Co these analyses shall be part of the submission HC The applicant is advised to prepare the Dec Canada's Declaration of Conformity form. I Standards under the Medical Devices Regular medical devices. USFDA Guidance for Industry and FDA Staff - Reco
СН3.5	IMDRF	1	Analytical Performance	NO CONTENT AT THIS LEVEL	
CH3.5.01	IMDRF	2	Stability of Specimen(s)	 Information regarding and studies to support the stability, storage and where appropriate, transport, of all of the specimen type(s) identified in the labelling, including any and all recommended additives (e.g. anticoagulants) is to be provided in this section. This should include: a) For each specimen type identified in the labelling, a description of the recommended storage parameters and when applicable, transport conditions (e.g. duration, temperatures and freeze/thaw cycles). b) A justification on the selection of the studies performed. c) Provide summary of the evidence that falls within this category d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR e) A discussion of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject device 	
CH3.5.01	IMDRF	3	[Study description,	NO CONTENT AT THIS LEVEL	
.1			study identifier, date of initiation, date of completion]	This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	

l or international standard as part of demonstration of ains Standards Data Report for 510(k)s (FDA Form 3654)

vith the current national standards, industrial standards.

pre-submission analyses conducted by an official laboratory Controle de Qualidade em Saúde) in Brazil. The reports of sion.

eclaration of Conformity to recognized standards using Health n. Refer to the Guidance Document: Recognition and Use of gulations and the current list of recognized standards for

ecognition and Use of Consensus Standards

Page 25 of 52

		_			
CH3.5.01	IMDRF	4	Summary	 For example, the structure will look something like this Level 3: Storage of serum samples for 7 days at 2-8°C or 4 days at -20°C. Level 4: Summary Level 4: Full Report Level 3: Validation of 3 freeze/thaw cycles for serum samples Level 4: Summary Level 4: Full Report A summary of the specific study described in the custom heading above. 	
.1.1	IWIDKI	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.01 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.01 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.02	IMDRF	2		 Studies to support the validity of specimen type(s) used in the analytical and clinical studies as representative of all of the sample type(s) identified in the labelling, including any and all recommended additives (e.g. anticoagulants), as well as contrived specimens used in certain analytical studies are to be included in this section. This should include: a) A list of the specimen type(s) used, including any additives (e.g. anticoagulants), in each of the analytical performance studies. If the same specimens are used for all analytical studies this can be stated and the specimen type identified. b) For any or all of the analytical and clinical studies, if a particular specimen type(s) including additives (e.g. anticoagulants), has been chosen as representative of other specimen types identified in the labelling, this should be described and supported. c) If the preparation of the specimen has not followed the protocol described in the current labelling, this should be identified and validated. d) A justification of the selection of the studies performed. e) Provide summary of the evidence that falls within this category f) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR g) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device 	WHO PQ In addition, information should be provided methods. (Note: this applies, for example, t means).
CH3.5.02 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study	

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ed on the relationship of specimens collected by different e, to specimens that can be collected by a swab or by other

				alone.	
CH3.5.02 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.02 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.02 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.03	IMDRF	2	Metrological traceability of calibrator and control material values	 Evidence that support the metrological traceability of values assigned to calibrators and trueness control materials. This should include: a) A description of all calibrators and trueness control materials associated with the system. b) A justification of the selection of the studies performed. c) Provide summary of the evidence that falls within this category, including for example, methods and acceptance criteria for the metrological traceability to reference materials and/or reference measurement procedures and a description of value assignment and validation. d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR e) A statement of why this category of study is not applicable to this case. NOTES: i. Precision control materials used during analytical studies to establish the reproducibility to a reference material or a reference method. ii. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device 	$\frac{EU}{Where applicable, the accreditation status of the $
CH3.5.03 .1	IMDRF (ANVISA, EU, HC, TGA, USFDA)	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.03 .1.1	IMDRF (ANVISA, EU, HC, TGA, USFDA)	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.03 .1.2	IMDRF (ANVISA, EU, HC, TGA,	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

s of laboratories used in physical and mechanical testing.

ce for Industry and FDA Staff – Recognition and Use of

Page 27 of 52

	USFDA)				
CH3.5.03 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listings XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.04	IMDRF	2	Accuracy of Measurement	NOTE: The general term measurement accuracy is currently used to cover both trueness and precision, whereas this term was used in the past to cover only the one component now named trueness. While measurement trueness , affected by systematic error, is normally expressed in terms of bias, measurement precision , affected by random error, is naturally expressed in terms of standard deviation. Accuracy is affected by a combination of systematic and random effects that contribute as individual components of the total error of measurement.	
CH3.5.04 .1	IMDRF	3	Trueness	 This section should provide a summary of information and evidence relating to the trueness of the measurement procedure. Trueness measures apply to both quantitative and qualitative assays only when a reference standard or method is available. This should include: a) A rationale for the reference standard or method(s) used b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device 	CFDA NOTE If there are different applicable models contains summary of the evaluation of above project USFDA 510(k) This is equivalent to a "method comparison predicate device. JP Provide comparison studies, if it is investigation
CH3.5.04 .1.1	IMDRF	4	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.04 .1.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.04 .1.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.04 .1.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listings XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred.
					NOTE: Do not place PDFs here.

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ontained in the registration application, the test data and ects conducted on different models shall be submitted.

on study"; 510(k)s can compare to a reference standard OR a

igated by non-clinical samples.

e for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

Page 28 of 52

CH3.5.04 .2	IMDRF	3	Precision (Repeatability and Reproducibility)	 A summary of evidence that support the precision characteristics of the measurement of the subject IVD medical device is to be included in this section. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category, including: i. Repeatability estimates and a brief summary about the studies used to estimate, as appropriate, within-run variability. ii. Reproducibility estimates and a brief summary of the studies used to estimate, as appropriate, variability between days, runs, sites, lots, operators (intended users) and instruments. Such variability is also known as "Intermediate Precision". c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: i. Studies should include the use of specimens that represent the full range of expected analyte (measured) concentrations that can be measured by the product, as claimed by the manufacturer. ii. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section 	<u>CFDA NOTE</u> If there are different applicable models cont summary of the evaluation of above project
CH3.5.04 .2.1	IMDRF	4	[Study description, study identifier, date of initiation, date of completion]	regarding the subject IVD medical device. NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.04 .2.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.04 .2.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	
CH3.5.04 .2.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data associ This includes metadata and data line listings XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.05	IMDRF	2	Analytical Sensitivity	 Evidence that support the analytical sensitivity of the subject IVD medical device is to be included in this section. This may include studies to establish the limit of blank (LoB), limit of detection (LoD), and/or limit of quantitation (LoQ). This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. 	CFDA NOTE If there are different applicable models cont summary of the evaluation of above project <u>EU</u> Where applicable, the accreditation status of

ontained in the registration application, the test data and ects conducted on different models shall be submitted.

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ontained in the registration application, the test data and ects conducted on different models shall be submitted.

s of laboratories used in physical and mechanical testing.

		_		-	
				NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device	
CH3.5.05 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.05 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.05 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.05 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing: XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.06	IMDRF	2	Analytic Specificity	 Evidence that support the analytical specificity (interference, including as appropriate, selectivity, and cross reactivity) of the subject IVD medical device is to be included in this section. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device 	CFDA NOTE If there are different applicable models cont summary of the evaluation of above project <u>EU</u> Where applicable, the accreditation status of
CH3.5.06 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.06 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.06 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
СН3.5.06	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listings

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ontained in the registration application, the test data and ects conducted on different models shall be submitted.

s of laboratories used in physical and mechanical testing.

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ags in their native formats, such as, but not limited to: SAS;

Page 30 of 52

.1.3					XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred.
					NOTE: Do not place PDFs here.
CH3.5.07	IMDRF	2	High Dose Hook Effect	 Evidence that supports the absence of a high dose hook effect or prozone effect. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section 	
		-		regarding the subject IVD medical device	
CH3.5.07 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.07 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.07 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.07 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.08	IMDRF	2	Measuring Range of the Assay	 Evidence that support the measuring range (linear and non-linear measuring systems). This measuring range should include the lower limit of quantification. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. 	CFDA NOTE If there are different applicable models cont summary of the evaluation of above project <u>EU</u> Where applicable, the accreditation status of
				NOTE: The sponsor/applicant should explicitly address any existing regional regulatory	

ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**


ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ontained in the registration application, the test data and ects conducted on different models shall be submitted.

s of laboratories used in physical and mechanical testing.

				guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device	
CH3.5.08 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.08 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.08 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.08 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.5.09	IMDRF	2	Validation of Assay Cutoff	 Evidence that support the determining assay cut-off is to be included here. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section regarding the subject IVD medical device 	<u>EU</u> Where applicable, the accreditation status o
CH3.5.09 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.09 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.09 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.5.09 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred.



ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

s of laboratories used in physical and mechanical testing.

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

Page 32 of 52

					NOTE: Do not place PDFs here.
CH3.5.10	IMDRF	2	Validation of the Assay Procedure	 This section should provide a summary of information and evidence supporting the validity of the assay procedure in terms of important reaction conditions (e.g. reaction time, reaction temperature, reagent volume, reading time). This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement of why this category of study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the analytical performance study results provided in this section 	
				regarding the subject IVD medical device	
CH3.5.10 .1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.5.10 .1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.5.10 .1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	
CH3.5.10 .1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data asso This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; A contact the specific review division for for preferred. NOTE: Do not place PDFs here.
СН3.6	IMDRF	1	Other Studies	NO CONTENT AT THIS LEVEL	
CH3.6.1	IMDRF (ANVISA, CFDA, EU, HC, TGA, USFDA)	2	Electrical Systems: Safety, Mechanical and Environmental Protection, and Electromagnetic Compatibility	 Evidence supporting electrical safety, mechanical and environmental protection, and electromagnetic compatibility are to be included in this section. This should include: a) A justification of the selection of the studies performed. b) A summary of the evidence that falls within this category c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. 	
				 d) A statement of why this category of laboratory study is not applicable to this case. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device 	
CH3.6.1. 1	IMDRF (ANVISA,	3	[Study description, study identifier, date of	NO CONTENT AT THIS LEVEL	

ssociated with the test described in the custom heading above. tings in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to r further guidance on the specific data format that is**

Page 33 of 52

EU, HC, TGA,			
$TG\Delta$	initiation, date of	This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u>	
	completion]	each study under the parent heading. The sub headings below would be for this study	
USFDA)		alone.	
CH3.6.1. IMDRF 4	Summary	A summary of the specific study described in the custom heading above.	
1.1 (ANVISA,			
EU, HC,			
TGA,			
USFDA)			
CH3.6.1. IMDRF 4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k)
1.2 (ANVISA,	1		If referencing a standard, refer to Guidance
EU, HC,			Consensus Standards.
TGA,			
USFDA)			
CH3.6.1. Regional 4	Statistical Data		This is the location for statistical data assoc
1.3 (USFDA)	Stutistical Data		This includes metadata and data line listing
1.5 (051 Dit)			XPORT; XML; SGML; S-Plus; R files; AS
			contact the specific review division for fu
			preferred.
			preterreu.
			NOTE: Do not place PDFs here.
CH3.6.2 IMDRF 2	Software/Firmware	NO CONTENT AT THIS LEVEL	
		Studies and supporting information on the software design, development process and evidence of the validation of the software, as used in the finished IVD medical device, are	
		to be included in this section and the associated sub-sections. It should also address all of	
		the different hardware configurations and, where applicable, operating systems identified in	
		the labelling	
CH3.6.2. IMDRF 3	Software/Firmware	a) Specify the name of the software	HC
01	Description	b) Specify the version of the software - The version tested must be clearly identified	The level of concern associated with the sol
	_	and should match the release version of the software, otherwise justification must	
		be provided.	<u>USFDA 510(k)</u>
		c) Provide a description of the software including the identification of the IVD	a) Identify the level of concern (minor, mod
		medical device features that are controlled by the software, the programming	that level.
		language, hardware platform, operating system (if applicable), use of Off-the-shelf	
		software (if applicable), a description of the realization process.	USFDA NOTE:
		d) Provide a statement about software version naming rules, specify all fields and their	For guidance on what specific software doc
		meanings of software version, and determine the complete version of software and	and FDA Staff: Guidance for the Content of
		its identification version used for release.	Devices
CH3.6.2. IMDRF 3	Hazard Analysis	The Hazard Analysis should take into account all device hazards associated with the IVD	
02		medical device's intended use, including both hardware and software hazards.	
A CONTRACT OF			
		NOTE	
		NOTE:	
		NOTE: i. This document can be in the form of an extract of the software-related items from a	
		i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971.	
		i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971.	
CH3.6.2. IMDRF 3	Software Requirement	 i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971. ii. Hazard analysis, should address all foreseeable hazards, including those resulting from intentional or inadvertent misuse of the IVD medical device. 	
CH3.6.2. IMDRF 3	•	 i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971. ii. Hazard analysis, should address all foreseeable hazards, including those resulting from intentional or inadvertent misuse of the IVD medical device. The Software Requirements Specification (SRS) documents the requirements for the 	
	Software Requirement Specification	 i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971. ii. Hazard analysis, should address all foreseeable hazards, including those resulting from intentional or inadvertent misuse of the IVD medical device. The Software Requirements Specification (SRS) documents the requirements for the software. This typically includes functional, performance, interface, design, developmental, 	
	-	 i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971. ii. Hazard analysis, should address all foreseeable hazards, including those resulting from intentional or inadvertent misuse of the IVD medical device. The Software Requirements Specification (SRS) documents the requirements for the software. This typically includes functional, performance, interface, design, developmental, and other requirements for the software. In effect, this document describes what the 	
	-	 i. This document can be in the form of an extract of the software-related items from a comprehensive risk management documentation, described in ISO 14971. ii. Hazard analysis, should address all foreseeable hazards, including those resulting from intentional or inadvertent misuse of the IVD medical device. The Software Requirements Specification (SRS) documents the requirements for the software. This typically includes functional, performance, interface, design, developmental, 	

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

software stated and supported.

oderate, major) and include a description of the rationale for

ocumentation to submit, refer to the Guidance For industry of Premarket Submissions for Software Contained in Medical

Page 34 of 52

CH3.6.2. 04	IMDRF	3	Architecture Design Chart	Detailed depiction of functional units and software modules. May include state diagrams as well as flow charts.	
CH3.6.2. 05	IMDRF	3	Software Design Specification	The Software Design Specification (SDS) describes the implementation of the requirements for the Software Device. The SDS describes how the requirements in the SRS are implemented.	
CH3.6.2. 06	IMDRF	3	Traceability Analysis	A Traceability Analysis links together your product design requirements, design specifications, and testing requirements. It also provides a means of tying together identified hazards with the implementation and testing of the mitigations.	
CH3.6.2. 07	IMDRF	3	Software Life Cycle Process Description	A summary describing the software development life cycle and the processes that are in place to manage the various life cycle activities.	
CH3.6.2. 08	IMDRF	3	Software Verification and Validation	 a) Include an overview of all verification, validation and testing performed both inhouse and in a simulated or actual user environment prior to final release. b) Discussion to support why the evidence presented is sufficient to support the application. OR c) A statement of why this category of non-clinical laboratory study is not applicable to this case. NOTE Discussion should address all of the different hardware configurations and, where applicable, operating systems identified in the labelling. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the non-clinical study results provided in this section regarding the subject IVD medical device 	
CH3.6.2. 08.1	IMDRF	4	[Study description, study identifier, date of initiation]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.6.2. 08.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.2. 08.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.2. 08.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.6.2. 09	IMDRF	3	Revision Level History	Revision history log, including release version number and date.	NOTE. Do not place i Di's nere.
CH3.6.2. 10	IMDRF	3	Unresolved Anomalies (Bugs or Defects)	All unresolved anomalies in the release version of the software should be summarized, along with a justification for acceptability (i.e. the problem, impact on safety and performance, and any plans for correction of the problems).	
CH3.6.2. 11	IMDRF (USFDA,	3	Cybersecurity	Evidence to support the cybersecurity should be provided here. For example, but not limited to:	USFDA Guidance for Industry and Staff – "Content

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

ent of Premarket Submissions for Management of

Page 35 of 52

	HC)			 a) Cybersecurity vulnerabilities and risks analysis b) Cybersecurity controls measures c) Traceability matrix linking cybersecurity controls to the cybersecurity vulnerabilities and risks 	Cybersecurity in Medical Devices"
CH3.6.2. 12	IMDRF (USFDA, HC)	3	Interoperability	If the IVD medical device can communicate with other devices. Evidence to support the interoperability should be provided.	<u>USFDA</u> Guidance for Industry and Staff – "Design Recommendations for Interoperable Medica
СН3.6.3	IMDRF (ANVISA, EU, HC, TGA, USFDA)	2	Cleaning and Disinfection Validation	 Contains information on the validation of cleaning and disinfection instructions for reusable devices, including evidence to support maintenance of performance when subject to this procedure over a number of cycles that is representative of the IVD medical device's expected useful life. Information to be included in this section includes: a) If applicable, a discussion of how the number of cycles that is representative of the IVD medical device's expected useful life has been determined. b) A justification of the selection of the studies performed. c) A summary of the evidence that falls within this category d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR e) A statement of why this category of laboratory study is not applicable to this case. NOTES: i. This applies most typically in near patient testing involving whole blood. iii. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device. 	
CH3.6.3. 1	IMDRF (ANVISA, EU, HC, TGA, USFDA)	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.6.3. 1.1	IMDRF (ANVISA, EU, HC, TGA, USFDA)	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.3. 1.2	IMDRF (ANVISA, EU, HC, TGA, USFDA)	4	Full Report	The test report for the test described in the custom heading above.	<u>USFDA 510(k)</u> If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.3. 1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc: This includes metadata and data line listings XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
СН3.6.4	IMDRF	2	Usability/Human Factors	Studies specifically assessing the instructions and/or IVD medical device design in terms of impact of human behavior, abilities, limitations, and other characteristics on the ability of	•

n Considerations and Pre-market Submission ical Devices"

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

Page 36 of 52

				 the IVD medical device to perform as intended should be included here. This should include: a) State the test environment and relation to the intended use environment b) A justification of the selection of the studies performed. c) A summary of the evidence that falls within this category d) A discussion and conclusion to support why the evidence presented is sufficient to support the application. OR e) A statement of why this category of laboratory study is not applicable to this case. NOTES: i. If a clinical study has been conducted that includes usability/human factors endpoints, 	
				 i. If a chinical study has been conducted that includes usability/human factors endpoints, reference to the studies and endpoints should be made, but full results do not need to be repeated and should be included in Chapter 4 – Clinical Evidence. ii. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device. 	
CH3.6.4. 1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.6.4. 1.1	IMDRF	4	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.4. 1.2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.4. 1.3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred.
CH3.6.5	IMDRF	2	Stability of the IVD	NO CONTENT AT THIS LEVEL	NOTE: Do not place PDFs here.
CH3.6.5. 1	IMDRF	3	Claimed Shelf-life	 Contains details and evidence supporting the claimed shelf-life of the IVD medical device components (e.g. reagents, calibrators/reference materials, control material, any other components susceptible to degradation). Information provided in this section should include: a) A description of recommended environmental conditions for storage of the IVD medical IVD medical device (e.g. temperature, pressure, humidity, light conditions). b) A statement of the claimed shelf-life indicated as a period of time or any other means of appropriate quantification. c) An indication of the packaging used in any studies conducted in support of the shelf-life. If the packaging used in the studies differs from the final device packaging, a discussion of why the evidence can be consider valid in support of the claimed shelf-life. d) A description of the simulated transport conditions that the IVD was exposed to before 	ANVISA, TGA and EU For devices that do not have an expiration p multiple use), information regarding the est indicated as number of procedures to be pe time or any other means of appropriate qua

nce for Industry and FDA Staff – Recognition and Use of

sociated with the test described in the custom heading above. ings in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to c further guidance on the specific data format that is**

on period (e.g. electromedical equipment or other devices of estimated mean "lifetime". This mean "lifetime" can be performed with the device and/or its accessories, as a period of quantification.

CH3.6.5. 2.1	IMDRF	4	[Study description, study identifier, date of	NO CONTENT AT THIS LEVEL	
				 OR e) A rationale that, for an indefinite period, the storage conditions could not affect IVD medical device safety or performance. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device. 	
CH3.6.5. 2	IMDRF	3	In Use Stability	 Contains details and evidence supporting the stability during actual routine use of the IVD medical device (real or simulated), including all applicable components (e.g. reagents, reaction cartridges). This may include open vial stability and/or, for automated instruments, onboard stability. Information provided in this section should include: a) A description of recommended environmental conditions for use of the IVD medical device (e.g. temperature, pressure, humidity, light conditions). b) A justification of the selection of the studies performed. c) A summary of the evidence that falls within this category d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. 	ANVISA, TGA and EU For devices that do not have an expiration p multiple use), information regarding the est indicated as number of procedures to be per time or any other means of appropriate quar
CH3.6.5. 1.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing: XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.
CH3.6.5. 1.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.5. 1.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.5. 1.1	IMDRF	4	[Study description, study identifier, date of initiation, date of completion]	NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject device. NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
				 the start of shelf-life studies. e) A justification of the selection of the studies performed. f) A summary of the evidence that falls within this category g) A discussion and a conclusion to support why the evidence presented is sufficient to support the claimed shelf-life. OR h) A rationale that, for an indefinite period, the storage conditions could not affect IVD medical device safety or performance. 	

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

n period (e.g. electromedical equipment or other devices of estimated mean "lifetime". This mean "lifetime" can be performed with the device and/or its accessories, as a period of pantification.

			initiation, date of completion]	This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.6.5. 2.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.5. 2.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.5. 2.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred.
CH3.6.5. 3	IMDRF	3	Shipping Stability	 Contains details and evidence supporting the tolerance of IVD medical device, or if provided separately, the components (e.g. reagents, calibrators/reference materials) to the specified or expected shipping conditions. Information provided in this section should include: a) An indication of environmental conditions for correct shipment of the IVD medical device (temperature, pressure, humidity, light conditions, mechanical protection etc.). b) A justification of the selection of the studies performed. c) A summary of the evidence that falls within this category d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR e) A rationale that, for an indefinite period, the storage conditions could not affect IVD medical device safety or performance. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD 	NOTE: Do not place PDFs here. <u>ANVISA, TGA and EU</u> For devices that do not have an expiration p multiple use), information regarding the est indicated as number of procedures to be per time or any other means of appropriate quare
CH3.6.5. 3.1	IMDRF	4	[Study description, study identifier, date of initiation, date of completion]	medical device. NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created for each study under the parent heading. The sub headings below would be for this study alone.	
CH3.6.5. 3.1.1	IMDRF	5	Summary	A summary of the specific study described in the custom heading above.	
CH3.6.5. 3.1.2	IMDRF	5	Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidance Consensus Standards.
CH3.6.5. 3.1.3	Regional (USFDA)	5	Statistical Data		This is the location for statistical data assoc This includes metadata and data line listing XPORT; XML; SGML; S-Plus; R files; AS contact the specific review division for fu preferred. NOTE: Do not place PDFs here.

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

n period (e.g. electromedical equipment or other devices of estimated mean "lifetime". This mean "lifetime" can be performed with the device and/or its accessories, as a period of uantification.

ce for Industry and FDA Staff – Recognition and Use of

ociated with the test described in the custom heading above. ngs in their native formats, such as, but not limited to: SAS; ASCII; Molfiles; and Excel. **The applicant is advised to further guidance on the specific data format that is**

Page 39 of 52

СН3.7	IMDRF, RF (HC, USFDA)	1	Analytical Performance and Other Evidence Bibliography	 a) A listing of published studies relevant to the context of this Chapter that involve this specific IVD medical device (e.g. analytical specificity, analytical sensitivity) b) A legible copy of key articles, including translation where applicable to meet the regulators language requirements. c) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. OR d) A statement that no literature related to the IVD medical device was found. 	
СН3.8	IMDRF	1	Other Evidence	 Heading for other information that may be important to the submission but that does not fit in any of the other headings of this chapter. For example, for tests performed to ensure the safety and/or performance of the IVD medical device that are not delineated in the rest of the Chapter 3. In addition a) Describe the purpose of the test, the risk/safety issue the test is addressing; the test methods and results of the test b) A justification of the selection of the studies performed. c) A summary of the evidence that is being submitted under this heading d) A discussion and a conclusion to support why the evidence presented is sufficient to support the application. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the study results provided in this section regarding the subject IVD medical device. 	
CH3.8.1	IMDRF	2	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone.	
CH3.8.1. 1	IMDRF	3	Summary	A summary of the specific study described in the custom heading above.	
CH3.8.1. 2	IMDRF		Full Report	The test report for the test described in the custom heading above.	USFDA 510(k) If referencing a standard, refer to Guidanc Consensus Standards.
CH3.8.1. 3	Regional (USFDA)	3	Statistical Data		This is the location for statistical data asso This includes metadata and data line listin XPORT; XML; SGML; S-Plus; R files; A contact the specific review division for f preferred. NOTE: Do not place PDFs here.

ance for Industry and FDA Staff – Recognition and Use of

ssociated with the test described in the custom heading above. tings in their native formats, such as, but not limited to: SAS; ; ASCII; Molfiles; and Excel. **The applicant is advised to or further guidance on the specific data format that is**

Row ID	Heading Clas & Level	S	Heading	Common Content	Regional Content
CH4.1	IMDRF	1	Chapter Table of Contents	a) Includes all headings for the chapter.b) Specifies the page number for each item referred to in the table.	
CH4.2	IMDRF	1	Overall Clinical Evidence Summary	 a) This should be a brief (1-2 page) summary of the available clinical evidence being presented in support of the submission. The document should list the evidence presented, its characteristics (e.g. well-controlled studies, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, literature review) and provide a discussion of how this is considered sufficient to support request for marketing for the requested indications. A tabular listing of clinical studies may be included in this section. b) If any of the study IVD medical devices differ from the IVD medical devices to be marketed, including competitors' IVD medical devices, a description of these differences and their impact on the validity of the evidence in terms of support for the application. c) A discussion of the clinical evidence considered for the IVD medical device and support for their selection (i.e. what type of evidence was considered and why they were or were not used) d) Discussion to support why the evidence presented is sufficient to support the application. 	 <u>EU and TGA NOTE:</u> Clinical evidence is always required, regardless <u>HC</u> a) Provide the Investigational Testing Authoric conducted under an Investigational Testing b) If applicable, provide the clinicaltrials.gov is clinicaltrials.gov. <u>USFDA PMA and 510(k)</u> Does not limit the page number for the summar <u>USFDA, HC, ANVISA and JP</u> If no clinical evidence is being provided, discuss
CH4.2.1	IMDRF	2	Expected Values/Reference Ranges	This section should include information on what values to expect in healthy normal patients versus affected patients.	
СН4.2.2	IMDRF (EU, CFDA, TGA)	2	Clinical Evidence Evaluation Report	a) A clinical evidence evaluation report reviewed and signed by an expert in the relevant field that contains an objective critical evaluation of all of the clinical data submitted in relation to the IVD medical device.b) A complete curriculum vitae, or similar documentation, to justify the manufacturer's choice of the clinical expert.	
СН4.2.3	IMDRF	2	IVD medical Device Specific Clinical Studies	NO CONTENT AT THIS LEVEL Clinical study information under this heading should be grouped by study	
CH4.2.3. 1	IMDRF	3	[Study description, protocol #, date of initiation, date of completion]	 NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created <u>for</u> <u>each study</u> under the parent heading. The sub headings below would be for this study alone. For example, the structure will look something like this Level 3: EU Pilot Study, CT4203, 2010-10-10 Level 4: Clinical Study Synopsis Level 4: Clinical Study Report Level 3: NA Controlled Study, CT4584, 2011-01-23 Level 4: Clinical Study Synopsis Level 4: Clinical Study Report 	
CH4.2.3. 1.1	IMDRF	4	Clinical Study Synopsis	 a) A summary of the specific study described in the custom heading above. b) 2-3 page summary document that presents a summary of: The key characteristics of the study (e.g. title of study, investigators, sites, study period (date of enrollment/date of last completed), objectives, methods, statistical 	USFDA PMA and 510(k) Does not limit the page number for the summar

horisation reference number for any clinical trials ing Authorisation in Canada. ov reference number for any clinical studies registered with

mary of the clinical information submitted

scuss why this is acceptable.

mary of the clinical investigations

Page 41 of 52

Dow ID	Heading Class	5	Uanding	Common Contont	Pagianal Contant
Row ID	& Level		Heading	Common Content design, interpretation of design, # patients, inclusion/exclusion criteria) and ii. Summary of the results of the analysis iii. Summary of conclusions related to the endpoints	Regional Content
				NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the components of the clinical study synopsis.	
CH4.2.3. 1.2	IMDRF	4	Clinical Study Report	 a) A clinical study report of the specific study described in the custom heading above. NOTES: The clinical study report should include elements such as the investigational plan/study protocol, protocol changes and deviations, description of patients, data quality assurance, analysis/results. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the components of the clinical study report. 	CFDA NOTE:The clinical trial report should be in accordancMedical Device Clinical Trial Quality ManageUSFDA PMA and 510(k)http://www.fda.gov/MedicalDevices/DeviceRegationalDeviceExemptionIDE/ucm046717.htm
CH4.2.2. 1.3	Regional (USFDA)	4	Clinical Study Data		USFDA The sponsor/applicant should explicitly address clinical study and data provided in this section regulatory guidance refers to Special Controls document, special controls guidance, special co The Center for Devices and Radiological Healt clinical data in electronic (non-PDF) form as su submission. http://www.fda.gov/MedicalDevices/DeviceRef ketSubmissions/ucm136377.htm
CH4.2.4	IMDRF (HC, JP, TGA, USFDA)	2	Clinical Literature Review and Other Reasonable Known Information	 a) Clinical literature review that critically reviews available information that is published, available, or reasonably known to the applicant/sponsor that describes safety and/or performance of the IVD medical device b) A legible copy of key articles, including translation where applicable to meet the regulators language requirements. OR c) A statement that no literature related to the IVD medical device was found. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the clinical study and data provided in this section regarding the subject IVD medical device 	
СН4.3	Regional (USFDA)	1	IRB Approved Informed Consent Forms		<u>USFDA</u> Copies of IRB approved informed consent form

nce with the Medical Device Registration Regulations, the gement Specification, and relevant clinical guidelines.

RegulationandGuidance/HowtoMarketYourDevice/Investi tm#sugforforidepro

ess any existing regional regulatory guidance related to the on regarding the subject device. In this instance regional ls in a device specific regulation, device-specific guidance controls guideline, and Statutory or Regulatory criteria.

alth (CDRH) accepts and encourages the inclusion of supporting material to a premarket (PMA or 510(k))

RegulationandGuidance/HowtoMarketYourDevice/Premar

orms are to be provided here.

Page 42 of 52

Row ID	Heading Clas & Level	SS	Heading	Common Content	Regional Content
CH4.4	Regional (USFDA)	1	Investigators Sites and IRB contact information		 <u>USFDA</u> Investigators and study administrative structur appropriate): a) Investigators (who signed the Investigator CV b) Sites-Site number as reflected in the study different from the above c) Sponsor-address and regulatory contact in d) Contract Research Organization (CRO), i e) 5. Laboratory facilities (central lab and/or contact information
СН4.5	IMDRF	2	Other Clinical Evidence	NO CONTENT AT THIS LEVEL This heading for other information that may be important to the submission but that does not fit in any of the other headings of this chapter.	
СН4.5.1	IMDRF	3	[Study description, study identifier, date of initiation, date of completion]	NO CONTENT AT THIS LEVEL This heading should be CUSTOM AND BASED ON STUDY DETAILS and created for each study under the parent heading. The sub headings below would be for this study alone.	
CH4.5.1. 1	IMDRF	4	Summary	 A summary of the specific study described in the custom heading above. NOTES: i. Should not include market history ii. The sponsor/applicant should explicitly address any existing regional regulatory guidance related to the clinical study and data provided in this section regarding the subject IVD medical device 	
CH4.5.1. 2	IMDRF	4	Full Report	The test report for the test described in the custom heading above.	
CH4.5.1. 3	Regional (USFDA)	4	Statistical Data		This is the location for statistical data associate This includes metadata and data line listings in XPORT; XML; SGML; S-Plus; R files; ASCII contact the specific review division for furth preferred. NOTE: Do not place PDFs here.

ure information should be provided, including (as tor agreement)-name, address, telephone # (contact info), dy report in reference to the investigator, address if information , if applicable-name, address, and contact information or local lab that participated in the study)-name, address,

ated with the test described in the custom heading above. in their native formats, such as, but not limited to: SAS; CII; Molfiles; and Excel. **The applicant is advised to ther guidance on the specific data format that is**

Row ID	Heading Class & Level	Heading	Common Content	Regional Content
CH5.1	IMDRF 1 (ANVISA, EU, HC, TGA, USFDA)	Chapter Table of Contents	a) Includes all headings for the chapter.b) Specifies the page number for each item referred to in the table.	
CH5.2	IMDRF, RF 1 (ANVISA, CFDA, EU, HC, TGA, USFDA)	Product/Package Labels	Samples of the primary and secondary packaging labels but exclusive of labels for shipping. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to labelling the subject IVD medical device	 <u>ANVISA</u> a) According to Brazilian Legislation all informations shall be in Brazilian-Portuguese. b) Specific requirements of labelling content are c) (PDFs of) the artwork of the labels will need to be provided.
				 <u>CFDA</u> a) Labels shall conform to the requirements of M Regulations. b) Reagents labels must be in Chinese and batcher c) The labels and the Chinese versions approved of departments shall be submitted as for imported provided and the context of the submitted as for the submitted as for imported provided and the context of the submitted as for imported provided and the context of the submitted as for imported provided and the context of the submitted as for the submitted as
				 <u>EU</u> a) (PDFs of) labels will need to be provided for secondary packaging. b) For Own Brand labelling, packaging and IFU provided.
				 <u>HC NOTES</u> a) All labelling must be provided in English or F upon request. b) Labelling for near-patient devices must also be
				TGA NOTES The labels and instructions for use (including any a) meet the requirements of Essential Principle 1 b) be in English and legible when viewed on scru c) include the Australian sponsor's contact detail
				If the applicant is including draft labels, artist improvide:a) the mock-up as full size suitable for A3 printib) a statement as to where and how the batch/se displayed
				<u>USFDA PMA:</u> a) Follow device labelling regulations found in 2

CHAPTER 5 – LABELLING AND PROMOTIONAL MATERIAL

ormation associated with the device, including labelling,

t are established by ANVISA's regulation. eed to be provided for device. nal labels, (PDFs of) stickers with local information will

of Medical Device Instructions and Label Management

tches of the sub-components must be marked on the labels ved or recognized by overseas government competent ed products.

for device labels as well as labelling of primary and

IFU of both the OBL and the OEM will need to be

or French, both official languages are to be available

so be provided in French and English

any package inserts) must ple 13 screen and printed letails to meet Regulation 10.2

t impression or mock-up labels, the applicant needs to

rinting ch/serial number/ date of manufacture/expiry date/ will be

l in 21 CFR Part 801 and 21 CFR 809.10

Page 44 of 52

CH5.3	IMDRF, RF (ANVISA, EU, HC, TGA, USFDA)	1 Package Insert/Instructions for Use 1 Insert/Instructions for Use 1 Insert/Instruct	Package Insert/Instructions for Use included in the package, when required or provide support for why this element is not applicable. NOTE: The sponsor/applicant should explicitly address any existing regional regulatory guidance related to labelling the subject IVD medical device	 ANVISA a) According to Brazilian Legislation all informshall be in Brazilian-Portuguese. b) Specific requirements of labelling content at c) The current version of the instruction for used (PDFs of) the artwork of the IFU will need to the current version of the instruction approach and imported products, the applicants shall suinstruction approved or recognized by overseas c) The product instructions shall be submitted in identical text shall be submitted. EU a) At minimum the IFU in a relevant acceptable national law, should be provided. Further law during audits. b) (PDFs of) labels will need to be provided for secondary packaging. c) For Own Brand labelling, packaging and IF provided. HC NOTES: a) All labelling must be provided in English or upon request. b) Labelling for near-patient devices must also c) Package inserts include a summary of clinic d) The current version of the instruction for use for the requirements of Essential Principle e) be in English and legible when viewed on set f) include the Australian sponsor's contact det If the applicant is including draft labels, artist in provide: c) the mock-up as full size suitable for A3 print d) a statement as to where and how the batch/displayed
CH5.4	IMDRF, RF (ANVISA, EU)	1 e-labelling	 a) For eligible IVD medical devices and stand-alone software, the applicant needs to identify which form of e-labelling is being used in case of e-labelling (e.g. electronic storage system or built-in system, website). b) Provide details of risk management in relation to e-labelling. If this is part of the overall 	EU For fixed installed IVD medical devices provide with the device itself as well as description of p

ormation associated with the device, including labelling,

t are established by ANVISA's regulation. use must be informed. to be provided for device.

pplicant/agent shall compile the product instructions in Compilation Guiding principles for Instructions of IVD l guiding principles.

l submit the original text and Chinese version of as government competent department.

d in two copies and a declaration the two copies are

able language, required by Notified Bodies following their language version will need to be available for verification

for device labels as well as labelling of primary and

IFU of both the OBL and the OEM will need to be

or French, both official languages are to be available

so be provided in French and English nical data use must be stated.

g any package inserts) must ple 13 a screen and printed letails to meet Regulation 10.2

t impression or mock-up labels, the applicant needs to

rinting ch/serial number/ date of manufacture/expiry date/ will be

l data

ide text message / information which will be given on or f place where it would be placed

Page 45 of 52

CH5.5	IMDRF (HC,	1	Patient Labelling	 risk management, refer to it here c) A description of the procedure and operations on providing IFU's when requested d) Provide written information for user Information on webpage where IFU and further information can be found in relevant languages. e) Description on how the requirements detailed for the website have been met. Labelling directed at the patient other than the package insert, such as informational 	
0110.0	USFDA)	1	I attent Eastening	material written to be comprehended by the patient or lay caregiver	
CH5.6	IMDRF (ANVISA, EU, HC, TGA, USFDA)	1	Technical/Operators Manual	Labelling directed to the technical users and operators of IVD medical devices focusing on the proper use and maintenance of the IVD medical device	
CH5.7	Regional (HC)	1	Product Brochures		 HC a) Draft product brochures available at the tim b) The sponsor/applicant should explicitly add labelling the subject device
CH5.8	IMDRF (ANVISA, EU, HC, TGA, USFDA)	1	Other Labelling and Promotional Material	Heading for other information that may be important to the submission but that does not fit in any of the other headings of this chapter.	

time of application ddress any existing regional regulatory guidance related to

Row ID			Heading	Common Content	Regional Content	
CH6A.1	Regional (USFDA)	1	Cover Letter		USFDA PMA Any PMA submission (including modular PMA) letter containing the information described in C NOTE: Quality Management System procedure procedures for the design and manufacture of the	
CH6A.2	IMDRF (TGA, JP USFDA)	1	Chapter Table of Contents	a) Includes all headings for the chapter.b) Specifies the page number for each item referred to in the table.		
СН6А.З	IMDRF (TGA, JP, USFDA)	1	Administrative	NO CONTENT AT THIS LEVEL. Administrative information needed to evaluate the premarket submission related to the QMS		
CH6A.3. 1	IMDRF (CFDA, TGA, JP, USFDA)	2	Product Descriptive Information	Abbreviated description of the IVD medical device, operating principles and overall manufacturing methods	USFDA PMA Description of the device should also include p numbers, product code and intended use.	
CH6A.3. 2	IMDRF, RF (ANVISA, CFDA, HC, JP, TGA, USFDA)	2	General Manufacturing Information	 a) Address and contact information for all sites where the IVD medical device or its components are manufactured. b) Where applicable, addresses for all critical subcontractors, such as outsourced production, critical component or raw material production (e.g. antigens, monoclonal antibodies), and sterilisation, will need to be provided. 	USFDA PMA NOTE This information is typically submitted to FDA	
СН6А.3. 3	IMDRF, RF (TGA, USFDA)	2	Required Forms	Any regional specific forms to be completed associated with Quality Management Systems in the premarket review process		
CH6A.4	IMDRF (TGA, USFDA, WHO PQ)	1	Quality management system procedures	 High level quality management system procedures for establishing and maintaining the quality management system such as the quality manual, quality policy, quality objectives, and control of documents and records <i>ISO 13485 Elements– SOPs to satisfy clause 4</i> 	USFDA PMA Quality System Procedures (outline of the quality WHO PQ a) A list of all current quality management SO b) Risk management	
СН6А.5	IMDRF (TGA, USFDA)	1	Management responsibilities procedures	Procedures that document the management commitment to the establishment and maintenance of the QMS by addressing quality policy, planning, responsibilities/authority/communication and management review. <i>ISO 13485 Elements – SOPs implementing clause 5</i>		
СН6А.6	IMDRF (TGA, USFDA, WHO PQ	1	Resource management procedures	Procedures that document the adequate provision of resources to implement and maintain the QMS including human resources, infrastructure and work environment. <i>ISO 13485 Elements – SOPs implementing clause 6</i>	WHO PQ a) Staff organogram	
СН6А.7	IMDRF (TGA, USFDA)	1	Product realization procedures	High level product realization procedures such as those addressing planning and customer related processes ISO 13485 Elements – SOPs implementing sub clause 7.1 and 7.2		
CH6A.7. 1	IMDRF (TGA,	2	Design and development	Procedures that document the systematic and controlled development of the IVD medical device design from initiation of the project to transfer to production.	USFDA PMA 21 CFR 820.30 Design Controls	

(As) of quality system information would need a cover
Chapter 1 under the Cover Letter heading

lures included in a PMA submission to the USFDA are f the specific device that is the subject of the PMA.

e pictures, proprietary name, common name, model

OA in the Cover Letter.

ality system documentation structure)

SOPs

Page 47 of 52

Row ID	v ID Heading Class		Heading	Common Content	Regional Content	
	USFDA, WHO PQ)		procedures	ISO 13485 Elements – SOPs for implementing sub clauses7.3	WHO PQ a) Change control and Change notification SO	
CH6A.7. 2	IMDRF (TGA, USFDA, WHO PQ)	2	Purchasing procedures	 Procedures that document that purchased products/services conform to established quality and/or product specifications. ISO 13485 Elements – SOPs to implement sub clause 7.4 	USFDA PMA:a) Purchasing Controls - Proceduresb) Acceptance Activities ProceduresWHO POa) Supplier evaluation and controlb) Verification of purchased product	
CH6A.7. 3	IMDRF (TGA, USFDA)	2	Production and service controls procedures	 Procedures that document the production and service activities are carried out under controlled conditions. These SOPS address issues such as cleanliness of product and contamination control; installation and servicing activities; process validation; identification and traceability; etc. ISO 13485 Elements – SOPs implementing sub clause 7.5 	USFDA PMA a) Production and Process Controls b) Servicing Procedures	
CH6A.7. 4	IMDRF (TGA, USFDA)	2	Control of monitoring and measuring devices procedures	 Procedure that document that monitoring and measuring equipment used in the QMS is controlled and continuously performing per the established requirements. <i>ISO 13485 Element- SOPs for implementing sub clause 7.6</i> 	<u>USFDA PMA</u> Inspection, Measuring & Test Equipment Proce	
CH6A.8	IMDRF (TGA, USFDA, WHO PQ)	1	QMS measurement, analysis and improvement procedures	 Procedures that document how monitoring, measurement, analysis and improvement to ensure the conformity of the product and QMS, and to maintain the effectiveness of the QMS. <i>ISO 13485 Element – SOPS for implementing clause 8</i> 	 USFDA PMA: a) CAPA Subsystem Procedures b) Nonconforming Product Procedure(s) c) Complaint Handling Procedures d) Quality System Audit Procedures TGA Note that the following should be included in the a) Procedures for the notification to TGA and a QMS or to the kinds of medical devices man b) Procedures for the issue of advisory notices, authorities for product recall c) Procedures for required notification to the T and changes to the QMS WHO PQ a) Complaint handling and vigilance b) Control of non-conforming goods/processes 	
СН6А.9	IMDRF (TGA, USFDA)	1	Other Quality System Procedures Information	Heading for other information that may be important to the submission but that does not fit in any of the other headings of this chapter.		

P _S

ocedures

a this section: ad other regulatory authorities of substantial changes to the nanufactured res, including the required notification to regulatory

e TGA and other regulatory authorities of adverse events

Page 48 of 52

CHAPTER 6B – QUALITY MANAGEMENT SYSTEM DEVICE SPECIFIC INFORMATION

Row ID	Heading Clas & Level	SS	Heading	Common Content	Regional Content
CH6B.1	IMDRF	1	Chapter Table of Contents	a) Includes all headings for the chapter.b) Specifies the page number for each item referred to in the table.	
СН6В.2	IMDRF (TGA, USFDA)	1	Quality management system information	Documentation and records specific to the subject IVD medical device that results from the high level quality management system procedures for establishing and maintaining the quality management system such as the quality manual, quality policy, quality objectives, and control of documents, noted in Chapter 6A <i>ISO 13485 Elements – documentation specific to the subject device for the implementation of clause 4</i>	
СН6В.3	IMDRF (TGA, USFDA)	1	Management responsibilities information	Documentation and records specific to the subject IVD medical device that result from the implementation the management responsibilities procedures noted in Chapter 6A ISO 13485 Elements – documentation specific to the subject device for the implementation of clause 5	
CH6B.4	IMDRF (TGA, USFDA)	1	Resource management information	Documentation and records specific to the subject IVD medical device that result from the implementation the resource management procedures noted in Chapter 6A. <i>ISO 13485 Elements – documentation specific to the subject device for the implementation of clause 6</i>	
CH6B.5	Regional (HC)	1	Device Specific Quality Plan		HC The review requirement for a quality plan are m to ISO 10005. A quality plan should specify "w will be applied by whom and when to meet the contract". This information may be provided map, document matrix, table or text description link device requirements to the processes, resou producing that device.
CH6B.6	IMDRF (TGA, USFDA)	1	Product realization information	Documentation and records specific to the subject IVD medical device that results from the implementation of the high level product realization procedures noted in Chapter 6A. <i>ISO 13485 Elements – documentation specific to the subject device for the implementation of sub clause 7.1 and 7.2</i>	
CH6B.6. 1	Regional (ANVISA, TGA, USFDA)	2	Design and development information	 Documentation and records specific to the subject IVD medical device that results from the implementation of the design and development procedures noted in Chapter 6A. The source of this information is the Design and Development Records (e.g. DHF - Design History File). And "summary of changes" can be sent as a table indicating the change requested and how it impacts on design and process information previously informed. <i>ISO 13485 Elements – documentation specific to the subject device for the implementation of sub clause 7.3</i> 	 <u>USFDA PMA and ANVISA</u> Design Control Information a) Design Outputs - List of Essential Design C b) Design Validation- Justification for use of n <u>ANVISA</u> a) Receiving and Acceptance Activities define those related with the "essential design outperfor example, if among the essential design material, this is considered a "critical raw response)
CH6B.6. 2	IMDRF (TGA, USFDA)	2	Purchasing information	 Documentation and records specific to the subject IVD medical device that results from the implementation of purchasing procedures noted in Chapter 6A. <i>ISO 13485 Elements – documentation specific to the subject device for the</i> 	<u>TGA</u> List of suppliers of goods or services that affect suppliers) and a description of how purchasing

e not met by the ISO 13485 certificate alone, instead refer "which processes, procedures and associated resources he requirements of a specific project, product, process or ed in an application in the form of a flow chart, process on. A quality plan specific for the subject device should sources and projects used by the manufacturer in

Outputs f non-production units in validation testing, if applicable

ined for critical row materials. "Critical raw materials" are utputs" indicated at the Design and Development Control. gn outputs reference is made to specifications of raw w material".

fect product conformity with requirements (critical ng requirements are fulfilled for these suppliers

Row ID	Heading Class & Level	Heading	Common Content	Regional Content
			implementation of sub clause 7.4	USFDA PMAa) List of Suppliers for the subject deviceb) Receiving and Acceptance activities for se
CH6B.6. 3	Regional (ANVISA, HC, JP, TGA, USFDA, WHO PQ)	2 Production and service controls information		 ANVISA, HC and TGA: a) Detailed Manufacturing Flow Diagram b) Summary of in-process acceptance activitie c) Process Validation Master Plan d) List of processes that have not be validated e) For each process validation considered crit i. Protocols/Procedures for monitoring and cosshould be fully described. iv. State the frequency of re-validation HC NOTES: a) Manufacturing flow diagram should provid for, the manufacture, processing, packagin device. Sufficient detail must be provided controls in place. b) If multiple facilities are involved in the mat facility must be submitted. If the informati <i>BP</i> a) A description of quality control tests and standards are sufficient to ensure tests and standards are sufficient to ensure c) Provide the test reports. OR d) A discussion of why this category of study DESEDA PMA Description of in-process acceptance activiti f) Process Validation master Plan e) List of process the will not be validated f) Protocols/Procedures for each validated process validation report

select suppliers

ties for subject device

ed itical to the safety and effectiveness of the device: ed process

ontrolling the process parameters of a validated process

ide a description of the methods used in, and controls used ng, storage and, where appropriate, the installation of the l to enable the judgement of the appropriateness of the

hanufacture of a device, the applicable information for each tion is identical for a number of sites, this should be stated.

standards in manufacturing for the final product.

Test

and standards. This should include the description why the e the effectiveness.

y is not applicable to this case.

nufacturing the PMA device

ties for subject device (optional)

d process tional/if available)

Page 50 of 52

Row ID	Heading Class & Level	S	Heading	Common Content	Regional Content
					 WHO PQ a) Full address, including latitude and longit b) Site floor plan c) Manufacturing flowchart including in-prod d) List of critical raw materials (including details of outsourced processes with direct product (conjugated antibodies, strips, reagents), out including details of the supplier for each processes ISO 13485 Elements – documentation specific clause 7.5
CH6B.6. 4	IMDRF (TGA, USFDA)	2	Control of monitoring and measuring devices information	 Documentation and records specific to the subject IVD medical device that results from the implementation of the control of monitoring and measuring device procedures noted in Chapter 6A. ISO 13485 Elements – documentation specific to the subject device for the implementation of sub clause 7.6 	
CH6B.7	IMDRF (TGA, USFDA, WHO PQ)	1	QMS measurement, analysis and improvement information	Documentation and records specific to the IVD medical subject device that results from the implementation of the QMS measurement, analysis and improvement procedures noted in Chapter 6A <i>ISO 13485 Elements – documentation specific to the subject device for the implementation of clause 8</i>	WHO PQ Batch/lot release SOPs
CH6B.8	IMDRF (TGA, USFDA)	1	Other Device Specific Quality Management System Information	Heading for other information that may be important to the submission but that does not fit in any of the other headings of this Chapter.	

gitude of the manufacturing facility(s)

process control points (details of the supplier of each material)

luct impact (e.g. outsourced manufacturing of components utsourced laboratory testing, packaging, printing, etc) cess

ific to the subject device for the implementation of sub

DOCUMENT REVISION HISTORY

Version	Description of Changes	Author	Date

Page 52 of 52